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FOREWORD 
 
The Trent Working Group on Acute Purchasing was set up to enable purchasers to share 
research knowledge about the effectiveness and cost-effectiveness of acute service 
interventions and determine collectively their purchasing policy. The Group is facilitated by 
The School of Health and Related Research (ScHARR), part of the Trent Institute for Health 
Services Research, the ScHARR Support Team being led by Professor Ron Akehurst and 
Dr Nick Payne, Consultant Senior Lecturer in Public Health Medicine. 
 
The process employed operates as follows. A list of topics for consideration by the Group is 
recommended by the purchasing authorities in Trent and approved by the Health Authority 
And Trust Chief Executives (HATCH) and the Trent Development and Evaluation 
Committee (DEC). A public health consultant from a purchasing authority leads on each 
topic assisted by a support team from ScHARR, which provides help including literature 
searching, health economics and modelling. A seminar is led by the public health consultant 
on the particular intervention where purchasers and provider clinicians consider research 
evidence and agree provisional recommendations on purchasing policy. The guidance 
emanating from the seminars is reflected in this series of Guidance Notes which have been 
reviewed by the Trent DEC, chaired by Professor Sir David Hull. 
 
In order to share this work on reviewing the effectiveness and cost-effectiveness of clinical 
interventions, The Trent Institute’s Working Group on Acute Purchasing has joined a wider 
collaboration, InterTASC, with units in other regions. These are: The Wessex Institute for 
Health Research and Development and The University of Birmingham Department of Public 
Health and Epidemiology. 
 
 
 
 
 
 
 
Professor R L Akehurst 
Chairman, Trent Working Group on Acute Purchasing 
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SUMMARY 
 
The use of hyperbaric oxygen therapy (HBO) has been undertaken for the last three 
decades as part of the management of patients with oral cancer. HBO involves a patient 
breathing 100% oxygen whilst inside a treatment chamber at a pressure greater than sea 
level pressure (i.e. greater than one atmosphere). The patient must receive the oxygen by 
inhalation within a pressurised chamber. 
 
HBO has been used for a number of different therapeutic aims: 
  
- to prevent the occurrence of osteoradionecrosis (ORN); 
- to treat established cases of ORN; 
- to aid wound healing; 
- prior to the placement of endosseous implants in order to facilitate implant 
survival. 
 
Although the impact of oral cancer upon a person's physical and psychological well-being is 
great, the number of patients who may benefit from therapy is small. There are around 20 
new cases of oral cancer per year for a health authority with a population of 500,000 and 
only a proportion of these patients may benefit from HBO. There is potential to double the 
number of patients by including people affected by head and neck cancer as well as those 
with oral cancer. In addition, there is a wider pool of patients who may benefit from the use 
of endosseous implants. Current funding of this reconstructive procedure is limited.  
 
At present, the service provided does not allow equitable access across the Trent Region. A 
recent survey in the Region has shown that approximately one third of head and neck 
surgeons prescribe hyperbaric oxygen. Trent residents have been referred to a wide 
number of chambers including those at Plymouth, Bangor, Peterborough, Hull, Sheffield and 
Lincoln. In some units, a physician is not present when the treatment is given.  
 
The evidence for the use of HBO in the treatment of oral cancer is limited. Whilst there is 
some research evidence available, much is still unknown and there is a need for further 
research. In relation to the treatment of ORN, the weight of evidence supports the 
effectiveness of HBO but suggests that it might not be necessary for all patients. For the 
prevention of ORN, the evidence is unclear. Management protocols based on careful wound 
care and surgical technique may minimise the risk of ORN. The use of HBO should not be 
used as a substitute for the high quality management of patients. There is limited evidence 
to support the use of HBO prior to the placement of endosseous implants, but further 
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evidence is required. 
 
There is a need for better information systems pertaining to the diagnosis and management 
of people with head and neck cancer. There appears to be a lack of criteria for the use of 
HBO and work at a local and national level is required in order to produce clinical consensus 
on treatment. As this procedure is not without risk, patients need to have access to 
comprehensive information and this is difficult in the absence of agreed clinical guidance. 
 
In summary, it is recommended that HBO in the treatment of oral cancer is used in the 
context of a clear statement of clinical practice, fully informed consent, comprehensive 
information and the collection of clinical data that allows the analysis of benefits and risks. 
Patients should only receive HBO from a unit, which has the necessary quality controls both 
in respect to the pressure used and patient observation.  
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ABBREVIATIONS 
BHA British Hyperbaric Association 
CRC 
COM 
ECHM 
Cancer Research Campaign 
Chronic osteomyelitis 
European Committee for Hyperbaric oxygen 
HBO Hyperbaric Oxygen Therapy 
ORN 
RCT 
TO 
UHMS 
Osteoradionecrosis 
Randomised Controlled Trial 
Transmuscosal Oxygen 
Underseas and Hyperbaric Medicine Society 
 
 
  4 
1. AIM OF THE REVIEW  
  
The use of hyperbaric oxygen therapy (HBO) has been undertaken for the last three 
decades as part of the management of patients with oral cancer. 
 
Hyperbaric oxygen therapy involves a patient breathing 100% oxygen whilst inside a 
treatment chamber at a pressure greater than sea level pressure (i.e. greater than one 
atmosphere). The patient must receive the oxygen by inhalation within a pressurised 
chamber. 
 
HBO has been used for a number of different therapeutic aims: 
 
 to aid wound-healing; 
 to prevent the occurrence of osteoradionecrosis (ORN); 
 to treat established cases of ORN; 
 prior to the placement of endosseous implants in order to facilitate implant survival. 
 
Initially, HBO was used primarily for the prevention and treatment of ORN. It was proposed 
in the management of ORN, a condition characterised by endarteritis with tissue hypoxia 
and secondary fibrosis. A paucity of nutrient vessels and fibroblastic cells exists in the 
irradiated mandible. HBO was proposed for the management of ORN specifically because it 
has been shown to enhance neovascularisation in irradiated and other hypoxic tissues. 
 
These properties fall into two categories: 
 
- Leucocyte utilisation of hydrogen peroxide, and other reduced oxygen 
components as part of their bacterial activity; and 
- Oxygen itself as an inhibitor of gram positive and gram negative growth. 
 
With changes in radiation therapy dosage schedules, the incidence of ORN is falling. There 
are now increasing pressures to move towards HBO prior to the placement of endosseous 
implants. Some clinicians argue that this therapy is an essential part of a post-surgical 
reconstructive regime, and its use will lengthen implant survival.  
 
In this instance, it is proposed that HBO will enhance osteogenesis, collagen formation and 
angiogenesis, prolonging implant survival. 
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Other clinicians believe that HBO is not essential for implant survival. The published 
literature reflects these differences in opinion with regard to the benefits and role of HBO in 
the treatment of patients with oral cancer. 
 
The Centre for Health Services and Policy Research (Canada) undertook a review of the 
issue in 1992.
1
 At that time, no conclusions regarding the use of HBO were possible. A 
number of additional reviews and case studies have since been published allowing the issue 
of HBO to be assessed further. This Guidance Note re-examines the literature evidence 
base regarding the use of HBO in the management of oral cancer. The objective is to 
address the following primary questions: 
 
  Is the use of HBO effective in the prevention of osteoradionecrosis? 
  Is the use of HBO effective in the treatment of osteoradionecrosis? 
  Is HBO effective in promoting wound healing? 
  Can the use of HBO prior to the placement of endosseous implants improve 
implant survival rates? 
  Can the wider use of HBO lead to NHS resource saving (real or notional) 
through: 
 - reduced demand for in-patient hospitalisation relating to 
osteoradionecrosis; 
 - reduced length of in-patient stay for the treatment of failure to heal 
wounds; 
 - improved implant survival rate and reduced demand for repeat 
procedures/prostheses. 
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2. BACKGROUND 
 
2.1 DESCRIPTION OF THE UNDERLYING DISEASE 
 
Oral Cancer is defined by ICD10 codes as: C00 (lip); C02 (tongue); C03 (gum); C05 (hard 
palate); C06 (floor of the mouth and other unspecified areas). The majority of cancers in 
and around the mouth are squamous cell carcinomas of the mucous membrane.  
 
2.1.1 Incidence 
 
As with malignant tumours of other sites, oral cancer is a disease which is more common in 
advancing age. It shows a sharp rise in incidence after the age of 40 years. Incidence in 
younger patients, however, is increasing, highlighting the important need for a satisfactory 
long-term cure and optimal restoration of function. More recent reports
2,3
 have suggested 
that there may be a rising trend in incidence in young men. Oral cancer is more common in 
men than women. It is largely preventable, the principal risk factors being the use of tobacco 
(primarily cigarette smoking) and the consumption of alcohol. In combination, alcohol and 
tobacco show a synergistic relative risk. 
 
There is a time lag in obtaining reliable data. In 1993 there were 1,918 new cases of oral 
cancer registered in England and Wales, giving an incidence of 3.73 per 100,000 
population.
4
 Regional incidence varies throughout the United Kingdom, with higher rates 
seen in the Northern Regions. The incidence and mortality rates from oral cancer are higher 
in Scotland than in England and Wales. In Scotland there is no clear pattern of occurrence, 
but in England and Wales there is a distinct North/South gradient for cancer of the mouth in 
males, with a higher rate in the North of the country.
5
 Registrations in the Trent Region for 
the period 1990-1998 are shown in Table 1.  
 
The number of cases which would be registered per year for a health authority with a 
population of 500,000 is in the order of 19. 
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Table 1 Registrations of Oral Cancer in the Trent Region 1990 - 1998 
 
Sex Health Authority 1990 1991 1992 1993 1994 1995 1996 1997 1998 
F NORTH DERBYSHIRE 4 3 5 4 4 3 2 4 2 
 SOUTHERN DERBYSHIRE  4 3 5 8 9 5 11 9 9 
 LEICESTERSHIRE  11 10 20 7 8 13 20 16 7 
 LINCOLNSHIRE  11 8 6 9 7 4 9 10 4 
 NORTH 
NOTTINGHAMSHIRE 
4 3  3 4 1 7 10 10 
 NOTTINGHAM 9 5 10 4 6 5 10 7 9 
 BARNSLEY 4 2 1 3 4 1 4 7 1 
 DONCASTER 4  6 3 2 2 3 3 4 
 ROTHERHAM 2 3 1 3 3 8 2 6 1 
 SHEFFIELD 11 3 7 6 1 5 5 7 3 
F Total  64 40 61 50 48 47 73 79 50 
M NORTH DERBYSHIRE 5 9 8 8 11 14 5 6 3 
 SOUTHERN DERBYSHIRE 10 8 9 12 9 13 12 12 20 
 LEICESTERSHIRE 15 18 17 20 13 16 16 17 8 
 LINCOLNSHIRE 5 18 10 11 12 7 12 12 9 
 NORTH 
NOTTINGHAMSHIRE 
6 8 9 15 10 8 6 3 3 
 NOTTINGHAM 7 14 13 12 12 11 16 19 19 
 BARNSLEY 4 7 4 1 5 2 7 6 3 
 DONCASTER 12 8 4 9 10 7 8 3 9 
 ROTHERHAM 8 6 4 6 10 8 7 9 4 
 SHEFFIELD 13 14 7 14 10 6 12 16 14 
M Total  85 110 85 108 102 92 101 103 92 
Grand Total 149 150 146 158 150 139 174 182 142 
 
 
2.1.2 Prognosis and Mortality 
 
Binnie and Rankin
6
 have reviewed survival rates for oral cancer. Their analysis suggests 
that there has been little or no change in the five-year relative survival rate for oral cancer 
since 1950. 
 
Mortality rates differ according to site; with cancer of the lip showing the lowest rates. 
Mortality in the Trent Region for the period 1990 - 1998 is shown in Table 2. 
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Table 2 Deaths from Oral Cancer by District of Residence in the Trent Region 
 
Sex Health Authority 1990 1991 1992 1993 1994 1995 1996 1997 1998 
F NORTH DERBYSHIRE 1 1 4 0 0 1 0 1 1 
 SOUTHERN DERBYSHIRE  2 3 1 1 1 6 2 4 4 
 LEICESTER  8 6 3 10 8 6 5 8 5 
 LINCOLN 2 4 6 2 4 4 5 5 0 
 NORTH 
NOTTINGHAMSHIRE  
1 2 0 3 1 2 4 3 0 
 NOTTINGHAM  5 5 2 2 2 3 2 6 3 
 BARNSLEY  3 0 1 1 0 3 1 2 1 
 DONCASTER  0 4 0 2 2 0 0 0 3 
 ROTHERHAM  1 0 1 1 0 2 3 2 2 
 SHEFFIELD  3 4 4 2 2 5 3 8 1 
 SOUTH HUMBER       0 3 1 
F Total  26 29 22 24 20 32 25 42 21 
M NORTH DERBYSHIRE 2 3 6 4 4 3 3 4 2 
 SOUTHERN DERBYSHIRE 5 0 5 3 5 4 4 9 6 
 LEICESTERSHIRE 5 7 5 6 9 7 8 7 7 
 LINCOLNSHIRE  1 3 5 4 5 5 5 5 5 
 NORTH 
NOTTINGHAMSHIRE  
4 3 3 5 3 3 4 3 1 
 NOTTINGHAM  2 9 3 3 8 2 9 9 9 
 BARNSLEY  1 0 1 0 1 0 0 4 5 
 DONCASTER 6 1 3 6 7 4 1 1 3 
 ROTHERHAM  8 6 4 6 10 8 7 9 4 
 SHEFFIELD  0 1 3 0 1 3 2 3 4 
 SOUTH HUMBER       4 6 2 
M Total  28 31 42 34 52 33 44 60 53 
Grand Total 54 60 64 58 72 65 69 102 74 
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2.1.3 Histology  
 
Lip cancer and intra oral cancer have different risk factors and prognosis and should be 
considered separately. 
 
2.1.4 Lip Cancer 
 
The majority of carcinomas of the lip occur in males who work outdoors, who are fair 
skinned and exposed to excess sunlight.
7
 They are well differentiated and 90% occur on the 
lower lip. They tend to be less aggressive tumours and the nature of their site may lead to 
their early detection. Spread to surrounding tissues can occur and there is a potential for 
spread to local lymph nodes and distant sites. 
 
Although lip cancer is virtually unknown in individuals younger than forty years, its incidence 
in men increases sharply with age. Overall lip cancer incidence, however, has diminished 
during the last two decades. 
 
2.1.5 Intra Oral Cancer 
 
A range of intra oral sites may be affected. The development of the primary site is not 
clearly understood, but widespread dysplastic mucosa (field change) may exist. A certain 
percentage of oral cancer patients develop multiple primary tumours. Additional primary 
tumours are most likely to be seen in patients with gingival, floor of the mouth, lingual or 
buccal carcinomas. Retrospective studies of head and neck cancer have demonstrated an 
incidence of between 7% and 20% for multiple primaries. The outlook after the diagnosis of 
a second primary is very poor. Intra oral cancer also has the potential for local, regional and 
metastatic spread. Between 28% and 83% of patients have been reported as developing a 
local recurrence at the primary site. Of those individuals who do suffer a recurrence, 90% 
will do so in the first two years post initial diagnosis. The presence of a secondary cancer is 
associated with a significant reduction in survival time. The sites of predilection for 
secondary tumours are elsewhere in the oral cavity, the hypopharynx and the larynx. The 
risk is higher in those who do not change their original tobacco habit than in those who 
reduce or discontinue smoking.  
 
The site and size of the primary growth mainly influence the chance of metastatic spread. 
Cancers of the tongue and floor of the mouth show a higher tendency to local and regional 
metastasis than cancers of the lower lip. In midline or near midline cancers, contralateral 
and bilateral lymphatic spread is not uncommon. 
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The average duration of symptoms is usually around four to five months, ranging from a few 
weeks to up to one year.
8
 The majority of squamous cell carcinomas grow rather slowly. 
Occasionally, however, such cancers behave in a very aggressive way. 
 
Some oral cancers arise de novo and present without any prior mucosal changes. However, 
there are a number of lesions which may precede oral cancer. The following oral lesions are 
considered to carry a potential for malignant change: 
 
 Leukoplakia; 
 Erythroplakia; 
 Chronic hyperplastic candidiasis. 
 
Erythroplakia is defined as 'any lesion of the oral mucosa that presents as bright red velvety 
plaques which cannot be characterised clinically or pathologically as any other recognisable 
condition'.
9
 
 
Oral leukoplakia has been defined 'as a predominantly white lesion of the oral mucosa that 
cannot be characterised as any other definable lesion; some oral leukoplakias will transform 
into cancer'.
10
 Leukoplakias may occur either as a single, localised change of the oral 
mucosa, or as diffuse, often multiple lesions. The surface may be smooth or wrinkled. Many 
lesions are crossed by cracks or fissures. The site distribution shows world-wide 
differences, that are partly related to gender and tobacco habits. The percentage of 
malignant transformation also varies world-wide, probably as a result of the same factors. 
 
Candida albicans is a normal oral commensal. Under certain conditions the organism may 
produce acute or chronic infection. In chronic hyperplastic candidiasis, dense chalky 
plaques are formed. Cawson
11
 has drawn attention to the high incidence of malignant 
transformation in these lesions. 
 
Other conditions have been considered as possible pre-malignant lesions and these include 
erosive and atrophic Lichen Planus, Oral Submucous Fibrosis, and Discoid Lupus 
Erythematosis. However, it is not clear what proportion of these lesions may proceed to 
malignant transformation. 
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2.1.6 Risk and Protective Factors for Oral Cancer 
 
The possibility of an individual developing oral cancer depends upon his/her genetic 
predisposition and exposure to risk factors. There are a number of established and possible 
risk factors. The two major factors responsible for oral cancer are tobacco and alcohol 
consumption. It is well established that the use of tobacco whether chewed or smoked is an 
important risk factor for oral cancer and cancer of other extra-oral sites. Case control 
studies have demonstrated a dose response relationship for cigarette, cigar and pipe 
smoking as well as for alcohol consumption.
12
 The carcinogenic effects of tobacco and 
alcohol are synergistic rather than additive.
13
 
 
Poor oral hygiene and nutritional deficiencies have been cited as further risk factors.
6,14
 Iron 
deficiency has been shown to be linked to muscosal atrophy, which in its severest form is 
expressed as Plummer-Vinson Syndrome. Other risk factors such as candidiasis, herpes 
simplex or human papilloma virus infection have also been implicated in the aetiology of oral 
cancer. Other studies have shown a protective effect with the intake of vegetables and 
fish.
15
 The interaction of the implicated etiological factors and the host susceptibility is a 
complex one. The extent to which these factors exert a direct effect on the oral mucosa, or 
make it more responsive to other carcinogens is unclear. 
 
2.1.7 Pathology 
 
A clinical diagnosis of oral cancer must always be confirmed histopathologically. Malignant 
tumours of the oral squamous epithelium are intraepithelial carcinoma (carcinoma in situ), 
squamous cell carcinoma and variants of squamous cell carcinoma (verrucous carcinoma, 
spindle cell carcinoma and lymphoepithelioma). 
 
The pathologist’s ability to make a diagnosis of squamous cell carcinoma, is dependent on 
the receipt of an adequate oral mucosa biopsy specimen. 
 
2.1.8 Prognosis and Mortality 
 
Relative survival by district of residence within Trent is shown in Table 3. 
 
Recurrence rates vary considerably. For those individuals who do suffer a recurrence, 90% 
will do so in the first two years post primary diagnosis. The presence of a secondary 
neoplasm is associated with a significant reduction in survival time. The presence of a node 
or metastasis is also associated with poor prognosis. Between 17% and 47% of patients 
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who appear to be free of nodal disease go on to develop positive nodes following treatment. 
The salvage rate of previous treatment failures is poor. 
 
Table 3 Relative Survival for all Cases of Oral Cancer by District of Residence 
within Trent 
 
Years Since Diagnosis            0                   1                  2                  3                  4                  5 
Trent (587 Cases) 
% Relative Survival 
95% CL 
 
        100                73.5             64.5             59.9             56.9             53.3         
(100.0-100.0)   (69.8-77.1)   (60.6-68.5)   (55.8-63.0)   (52.9-60.9)   (49.2-57.3)  
N. Derbyshire (45 Cases) 
% Relative Survival 
95% CL 
  
         100              68.6             60.5             57.4              56.2            50.2  
(100.0-100.0)   (54.8-82.4)  (46.0-74.9)  (42.9-72.0)  (41.5-70.8)  (35.7-64.7) 
S. Derbyshire (59 Cases) 
% Relative Survival 
95% CL 
            
         100              83.3             65.8             65.3              55.4            49.8 
(100.0-100.0)   (73.4-93.3)  (53.5-78.1)  (52.8-77.7)  (42.7-68.2)  (37.1-62.5)   
 
Leicestershire (114 Cases) 
% Relative Survival 
95% CL 
  
         100                 76             65.6             61.2             61.1                59 
(110.0-100.0)   (67.0-84.0)  (56.7-74.5)  (52.1-70.3)  (52.0-70.2)  (49.8-68.2) 
Lincolnshire (78 Cases) 
% Relative Survival 
95% CL 
  
         100              78.1             73.6                65              57.9            58.8 
(100.0-100.0)   (68.6-87.6)  (63.3-83.8)  (54.1-75.9)  (46.8-69.0)  (47.7-69.9)  
N. Notts (45 Cases) 
% Relative Survival 
95% CL 
            
         100              64.8                59             55.7              55.3            49.5 
(100.0-100.0)   (50.6-79.0)  (44.5-73.5)  (41.1-70.3)  (40.7-69.9)  (35.1-63.9) 
Nottingham (73 Cases) 
% Relative Survival 
95% CL 
 
         100              64.9              54.7             49.3             48.3            47.1 
(100.0-100.0)   (53.8-75.9)  (43.3-66.2)  (37.8-60.7)  (37.0-59.7)  (35.9-58.3) 
Barnsley (26 Cases) 
% Relative Survival 
95% CL 
            
         100                 79              68.2             65.8               63              62.8 
(100.0-100.0)   (62.8-95.2)  (50.0-86.5)  (47.1-84.5)  (44.0-82.0)  (43.8-81.8) 
Doncaster (43 Cases) 
% Relative Survival 
95% CL 
            
         100                 67              65.6            62.3              63.5            52.2 
(100.0-100.0) (52.7-81.2)  (51.2-80.1)  (47.5-77.0)  (48.8-78.3)  (37.3-67.1)           
Rotherham (33 Cases) 
% Relative Survival 
95% CL 
            
         100                 84              79.2             71.7             70.8            66.5 
(100.0-100.0)   (70.8-97.2)  (64.6-93.8)  (55.6-87.8)  (54.4-87.2)  (49.7-83.4) 
Sheffield (71 Cases) 
% Relative Survival 
95% CL 
            
         100              70.6             59.1             53.4                 48            43.1 
(100.0-100.0)   (59.8-81.3)  (47.5-65.0)  (41.7-65.0)  (36.5-59.6)  (31.9-54.4) 
 
 
2.1.9 Treatment Modalities 
 
Early diagnosis of oral cancer should lead to better treatment results. A high proportion of 
the population attends the dentist and the oral cavity is easily examined. Yet, between 27% 
and 50% of patients present for treatment with late lesions. Scully
16
 analysed this delay in 
diagnosis and notes that many patients are elderly and delay visiting their doctor or dentist. 
Many wear dentures and ascribe ulceration to their dentures. Practitioners may have a low 
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index of suspicion and initially treat a lesion with antibiotics or steroids. Finally, oral cancer is 
not usually painful in the initial stages. 
 
Treatment options include surgery, radiation therapy, cryosurgery, CO2 laser surgery and, 
more recently, photodynamic therapy. Chemotherapy is reserved primarily as adjunctive 
therapy. Traditionally, the main treatment approaches for oral cancer are:  
 
 surgery alone;  
 surgery combined with radiotherapy; or  
 radiotherapy.  
 
Current activity data do not allow the proportion of patients currently receiving each of these 
options to be determined, since no out-patient radiotherapy data are available. The elective 
management of the neck at the time of the operation is a controversial matter. The value of 
elective neck dissection in improving survival has not yet been shown clearly. 
 
2.1.10 Surgery 
 
Excision and reconstruction together form the basis of the surgical management of oral 
cancer. Following surgery, the patients with advanced cancers are, in general, given 
adjuvant radiotherapy within six weeks. A small proportion of patients require the provision 
of suitable prosthetic rehabilitation which may require the surgical insertion of 
osseointegrated implants as part of combined surgical/prosthetic rehabilitation. In oral 
cancer cases, implants are often the only way in which a patient can be rehabilitated 
satisfactorily with an oral prosthesis. 
 
2.1.11 Radiotherapy 
 
There are two different methods of delivering radiotherapy. Teletherapy, or external beam 
irradiation, delivers a beam or irradiation to the tumour from a machine. In brachytherapy, 
the source or radiation is placed within or near to the tumour. 
 
Radiotherapy may be used as the only treatment for oral cancer, or in combination with 
other treatment modalities. It may be used pre- or post-surgery.  
 
ORN is a serious medical condition which can develop as a result of radiation therapy for 
oral cancer. The majority of all trauma-induced osteoradionecrosis of the mandible is 
caused by tooth extraction in the radiated jaw. ORN has been described as the 
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development of a hypovascular hypoxic, hypocellular state due to progressive radiation-
induced fibrosis.
17
 In practical terms it refers to exposed bone in a field of irradiation which 
has failed to heal for at least six months. Conventional treatment of ORN, generally referred 
to as 'conservative treatment', includes avoidance of local irritants, irrigation with a wide 
variety of agents, antibiotics and superficial sequestrectomies. If the disease does not 
respond, reconstructive surgery is undertaken.
18
  
 
The incidence of ORN has declined since the 1970s. Clayman
19
 extensively reviewed the 
literature on ORN and reported that prior to 1968 the incidence of ORN was 11.8%, falling 
to 5.4% after that date. In addition, Clayman reported that the five most recent studies 
reported a prevalence of ORN of only 1.1% in 424 patients who had teeth removed after 
radiotherapy. These patients received aggressive preventative dental care and the 
extractions were performed by experienced oral and maxillofacial surgeons. Brown
20
 also 
reports a decline in incidence levels, resulting from the more efficient use of radiation and 
improved dental care and follow-up.  
 
2.2 CURRENT SERVICE PROVISION  
 
Research in the Trent Region has shown that approximately one third of head and neck 
surgeons prescribe HBO. A survey of ENT, oral and maxillofacial surgeons in Trent showed 
that 12 out of the 16 respondents did refer patients for hyperbaric oxygen. There were 32 
referrals in the last 12 months from consultants in the Region who responded to the survey.  
   
Table 4 Number of Trent Patients Referred by Consultants Responding to 
Survey 
  
No. of 
Patients 
Referred 
Consultants Referring 
 
0 1 
1 5 
2 3 
3 1 
4 2 
10 1 
Unknown 1 
 
 
More detailed results of the survey are shown in Appendix A.  
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The majority of responses (13 of 16) to the Trent survey were from Maxillofacial consultants, 
suggesting than the majority of patients with ORN are treated within this specialty. 
Consultants in the Trent Region refer patients for the treatment of osteoradionecrosis (11 of 
12 respondents), pre- and post-radiation therapy in order to prevent osteoradionecrosis (4 
of 12), pre- and post-surgery in order to promote wound healing (5 of 12), and prior to the 
placement of endosseous implants in order to improve implant survival (7 of 12). 
 
Trent residents have been referred to a wide number of chambers including chambers at 
Plymouth, Bangor, Peterborough, Hull, Sheffield and Lincoln.  
 
The number of Trent residents attending the HBO facility at Plymouth over the last 2 years 
was as follows: 
 
Table 5  Number of Trent Patients Receiving Treatment at Plymouth Chamber Since 
1998 
 
 
Patient Year Area No of 
   'Dives' 
1 1998 Head 38 
2 1998 Head 35 
3 1998 Mandibular 13 
4 1998 Jaw 39 
5 1998 Mandibular 38 
6 1998 Jaw 42 
7 1998 Mandibular 33 
8 1999 Skull 40 
 
The numbers of patients attending the HBO facility at Peterborough since 1997 were: 
 
    1997  3 
    1998  6 
 1999  4 
 
This comprised patients from Leicestershire, Nottingham and Lincolnshire Health 
Authorities. 
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It is not known how many patients have been referred to local chambers run by the Multiple 
Sclerosis Society.  
 
2.2.1 The British Hyperbaric Association  
 
The British Hyperbaric Association (BHA) provides information regarding the availability of 
hyperbaric oxygen facilities in Britain. The BHA provides lists of the 25 member chambers 
which each offer emergency hyperbaric therapy. This list includes the chambers at Hull, 
Plymouth and Peterborough. 
 
A document entitled 'A code of good working practice for the operation and staffing of 
hyperbaric chambers for therapeutic purposes'
21
 has been adopted by members of the 
Association. The code has been accepted by the UK Department of Health. 
 
Table 6  Number of Patients Receiving Hyperbaric Therapy at BHA Chambers in 
Great Britain 
 1994 1995 1996 1997 
Diving Related Emergencies   262 270 258 349 
Hyperbaric Oxygen Emergency Cases 315 343 385 352 
Hyperbaric Elective Cases   346 425 639 673 
 
 
Table 7  Indications for Hyperbaric Therapy in Patients in 1997 at BHA Chambers 
 Number Percentage 
Decompression Illness 349 25.4% 
Carbon Monoxide Poisoning 352 25.6% 
Gas Embolism (Non-diving) 0 0% 
Soft Tissue Infections 32 2.3% 
Post Radiotherapy 
Other ECHM or UHMS indications 
112 
271 
8.2% 
19.7% 
Research 37 2.7% 
Other Indications 592 35.8% 
Total 
ECHM = European Committee for Hyperbaric Oxygen        
UHMS  = Underseas and Hyperbaric Medicine Society 
 100% 
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2.3 THE DELIVERY OF HYPERBARIC OXYGEN  
 
There are four conditions where hyperbaric oxygen is used following radiotherapy for oral 
cancer. They are: 
 
 the treatment of osteoradionecrosis;  
 prophylactically before and after surgery to prevent osteoradionecrosis; 
 the promotion of wound-healing; 
 before and after placement of implants. 
 
The use of HBO for the treatment and prevention of ORN has been advocated by some 
clinicians since the early 1970s. 
 
2.3.1 Criteria for Treatment 
 
The referral of patients in these categories varies widely; apparently, this is dependent on 
the lead surgeon involved with the case. Many individuals treated for oral cancer receive 
adjunctive radiotherapy. When the mandible is in the path of irradiation then well-described 
changes in the blood-supply to the bone cells occur.
17
 This results in an impaired ability for 
oxygen to reach the bone being regenerated. Regardless of its specific type, radiotherapy 
causes a decrease in the vascular supply of all tissues and compromises many other factors 
responsible for wound healing.
22,23
 As radiation dosage increases, fibroblast activity 
diminishes, and there is a progressive obliteration of tissue capillaries resulting in a 
decrease in their total number. Costantino et al.
17
 emphasised that radiation-damaged 
tissues cannot reverse these changes over time without therapeutic intervention. The 
irradiated bone loses its capacity to replace normal collagen and cellular components. When 
the bone breaks down from routine wear, it does not have the capacity to repair itself fully, 
owing to limitations imposed on it by the radiation-induced hypoxic, hypovascular state. The 
resultant bone and wound are incapable of increasing their metabolic requirements and 
nutrient supply to the point at which healing can occur. 
 
The blood supply to the mandible is of such a type as to make radiation damage most 
important. The dominant blood supply to the mandible varies with the region of the bone. 
The area of the posterior part of the mandible has a blood supply from the surrounding 
musculature, but that to the body of the mandible is largely from the inferior alveolar 
artery
24
. Severing this supply as would happen during surgery in this area, concomitant with 
stripping the periosteum from the bone, can reduce greatly the blood supply to the bone 
distal to the site of the osteotomy. In addition, it has been shown that there are age-related 
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changes in the intramedullary blood supply of the mandible.
25
 A significant proportion of 
adults over 55 have no functional intramedullary blood supply to the anterior part of the 
mandible. This is of significance as the incidence of oral cancer in the UK is greatly skewed 
towards the elderly.
26
 
 
Because of these changes in the blood supply, some surgeons chose to improve the 
regeneration of arterioles by using hyperbaric oxygen
27
 and prolonged courses of 
intravenous antibiotics. 
 
2.3.2 The Theory of Hyperbaric Oxygen Useage 
 
In a normal uncomplicated non-radiated wound, there is a steep oxygen gradient between 
the normal and the damaged tissue. A steep oxygen gradient appears necessary for the 
regeneration of blood capillaries and their penetration of the hypovascular area.
28
 In the 
normal wound this may be 0 to 5mm Hg in the centre, with levels of 50 to 60 mm Hg in the 
adjacent normal tissue, as measured by needle electrode or transcutaneous oximetry. In 
radiation damage, steep gradients are not found.
29
 
 
Marx et al.
30
 have shown that the oxygen tensions in the centre of an uncomplicated 
radiation-damaged area are about 5 to 10 mm Hg. They found a gradual improvement at  
1 cm intervals from the centre to the edge of the irradiated field which showed a gradual 
improvement in tissue oxygen tensions until the normal values of 55 to 60 mm Hg were 
found at the edge. During exposure of the tumour to hyperbaric oxygen at 2.4 atmospheres 
they found a 7 to 10 fold increase in oxygen tension at each 1 cm increment. This rise was 
also seen in the non-irradiated tissue outside the irradiated field. The shallow oxygen 
gradient previously found was magnified into a step gradient at each increment. This 
happened increasingly after repeated exposure to hyperbaric oxygen, until after 20 to 24 
treatments, the oxygen gradients at the increments were largely eliminated.
30
 
 
The mechanism for hyperbaric oxygen to enhance revascularisation of irradiated tissues is 
through the creation of steep oxygen gradients which are present normally in non-irradiated 
wounds. This is said to stimulate the process of tissue angiogenesis. A controlled study has 
shown that 100% oxygen at normal atmospheric pressure does not produce angiogenesis in 
irradiated tissue. Results were no different from those seen in air-breathing controls.
31
 
 
Kindwall argues that this mechanism demonstrates that there will be no effect until 
significant damage has already occurred. For this reason, complete prophylaxis would not 
appear to be feasible. He points out that more research is necessary to determine at which 
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point post-radiation HBO becomes useful, where vascular damage has not yet posed a 
clinical problem such as ulceration or osteoradionecrosis.
29
 
 
2.3.3 The Delivery of Hyperbaric Oxygen 
 
There are two types of HBO chambers in use, reflecting its different uses. The principal 
development has been for treating divers with decompression sickness (the 'bends'), and 
multiplace chambers (see figure 1) most commonly exist in well-established centres for 
diving, such as Plymouth, Bangor (North Wales), Aberdeen and Hull. The large chamber is 
pressurised with compressed air and the patients receive oxygen from a face-mask or hood, 
which is a tightly-sealed head tent. The chamber pressure can be brought up to 2.4 
atmospheres, which is sufficient for treatment involving osteoradionecrosis. An attendant is 
present inside the chamber and, at some centres, a physician is present also. There can be 
problems of claustrophobia for some patients, but an advantage of the multiplace chamber 
is that ill patients requiring nursing or close supervision can be treated. Patients sent to a 
multiplace centre usually require bed and breakfast accommodation to be arranged and 
funded. 
 
The other type of chamber is the monoplace one (see figure 2). These are present in many 
cities in the UK, and many are owned and operated by the Multiple Sclerosis Therapy 
Centre, a charitable organisation, for use by sufferers of Multiple Sclerosis. If the facility is 
within reasonable travelling distance, the patient can return home between 'dives'.  
 
The unit comprises a small plastic chamber which is filled with oxygen under pressure of 2 
to 2.4 atmospheres. These units are small and are run by nurses or other workers and are 
not supervised by a physician. They can cause greater claustrophobia than the multiplace 
chambers.  
 
 
Treatment Regime 
 
The treatment regime in both types of chamber is the same. The Marx Protocols
39
, which 
combine HBO and surgery in the prevention and management of osteoradionecrosis have 
become the standard of care. For the prevention of osteoradionecrosis, the 20/10 protocol is 
advocated: 20 'dives' of 90 minutes each pre-operatively, followed by 10 'dives' post-
operatively. For the treatment of established osteoradionecrosis, the 30/10 protocol is 
advocated with 30 initial 'dives' (See Appendix B for further details).  
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Figure 1 Example of Monoplace Chamber 
 
 
 
 
Figure 2 Example of Multiplace Chamber 
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2.3.4 Length of Benefit 
 
The effects of hyperbaric oxygen are usually evident after eight treatments and a plateau is 
reached after about 20-24, beyond which no further benefit is observed. Kindwall
29
 found 
that the level of angiogenesis four years after completion of the hyperbaric protocol was the 
same as at the completion of the protocol. Further studies were required to ascertain the full 
extent of benefit. 
 
2.3.5 Cost  
 
Detailed costs of treatment are available, and three examples are given: 
 
a) Medically Supervised at the Diving Diseases Research Centre at Plymouth 
 
20 sessions 2.4 atmospheres per day pre-op. 
10 sessions 2.4 atmospheres per day post-op. 
 
@ £55 per session = £1,650 
Accommodation @ £50 per day = £1,500 
Total = £3,150. 
 
b) Medically Supervised at the Peterborough District General Hospital 
 
The total cost is around £4,500. A breakdown of costs has been requested. 
 
c) Non-medically Supervised, at Sheffield Multiple Sclerosis Therapy Centre 
 
20 sessions 2.4 atmospheres per day pre-op. 
10 sessions 2.4 atmospheres per day post-op. 
 
@ £17 per session = £510 
Accommodation = nil 
Total = £510. 
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2.3.6 Side-effects of HBO 
 
The use of HBO is not without complications, risks or contraindications. These 
complications may arise from environmental or therapeutic factors. 
 
2.3.6.1 Environmental 
 
Patients receiving HBO enter a specialised environment. HBO chambers may be monoplace 
(patient only enters chamber) or multiplace (patient and provider enter chamber). There are 
potential changes within and without the chamber - the oxygen rich air may become 
explosive; sudden loss of pressure can result in decompression. 
 
2.3.6.2 Therapeutic 
 
There are a number of medical conditions and contraindications for the use of HBO. These 
are: 
 Pneumothorax; 
 Severe chronic obstructive pulmonary disease; 
 Optic neuritis; 
 Acute viral infection; 
 Upper respiratory infection; 
 Pregnancy; 
 Congenital Spherocytosis; 
 Patients with psychiatric problems; 
 Patients with prior thoracic or middle ear surgery. 
 
2.3.6.3 Complications 
 
Most of the complications arising from HBO therapy result from barometric pressure 
changes or oxygen toxicity. Some of the possible complications associated with HBO 
therapy are detailed below: 
 
 Eustachian tube dysfunction; 
 Tympanic membrane rupture; 
 Oxygen toxicity; 
 Ear, sinus or tooth pain; 
 Pneumothorax; 
 Middle ear haemorrhage; 
  23 
 Deafness; 
 Changes in vision; 
 Nausea, fatigue, claustrophobia. 
 
Middle ear barotrauma is the most common side-effect of HBO. It may be prevented by 
teaching autoinflation techniques or by the use of tympanostomy tubes for individuals who 
are unable to autoinflate their middle ear compartment.  
 
Progressive myopia has been observed in some patients undergoing prolonged periods of 
daily HBO. It usually reverses within a period of a few days to several weeks after the last 
therapy. 
 
A complete medical history and physical evaluation of the patient and knowledge of 
potential problems is essential. 
 
2.3.7 Side-effects  
 
A particular problem resulting from the administration of HBO is the feeling of 
claustrophobia which may result. For some patients this feeling is unacceptable and they 
are unable to complete the course of therapy.  
 
In general, whilst side-effects may occur, the benefits of HBO therapy are such that the 
potential for side-effects can be considered to be an acceptable risk. However, patients 
should be provided with information relating to risk as part of their informed consent for HBO 
therapy. 
 
Evidence on side-effects is reported in Table 8. 
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Table 8 Evidence on Adverse Events Related to HBO 
 
Author 
Date 
Country 
Aims of Study Patient 
Population 
Study 
Design Intervention Outcome Measures Results Comments 
Giebfried et 
al.
32
 
1986 
USA 
Case series – review of 
complications post HBO. 
101 patients. Retro-
spective. 
HBO for head 
and neck 
disease. 
15 year retrospective. 3 patients developed serious 
complications; (all 3 
experienced seizures; 1 
developed a stroke and 1 
sustained myocardial 
infarction). 
2 patients developed minor 
complications (eustachian 
tube dysfunction). 
 
Foster
33
 
1992 
USA 
To discuss the 
contraindications for, and 
complications resulting from, 
the use of HBO. 
  HBO.   Contra indications 
and complications 
discussed overall 
safety observed. 
Headley et 
al.
34
 
1991 
USA 
To study the effect of HBO 
on the growth of human 
squamous cell carcinoma 
Xenograft. 
Xenografts 
transplanted 
In nude mouse 
host. 
3 mouse 
groups: 
HBO 
given to 
half mice 
in each 
group. 
HBO. Xenografts growth. Xenograft growth almost linear 
in all mice. 
No statistical difference 
between mice given HBO or 
control mice. 
Study suggests that 
HBO has no effect on 
established tumour 
xenograft growth. 
Blanshard et 
al.
35
 
UK 
1996 
To measure the incidence 
and severity of middle ear 
barotrauma in patients 
undergoing HBO. 
82 Patients. Pro-
spective. 
HBO. The incidence of 
otalgia 1 hr; 19 hours 
after treatment. 
24 patients required insertion 
of ventilation tubes for 
intractable otalgia. 
 
Ross et al.
36
 
1996 
USA 
To examine the effect of 
HBO on myopia. 
8 subjects 
receiving out-
patient HBO (all 
had mandibular 
ORN or non 
healing soft 
tissue necrosis). 
Pro-
spective. 
Vision tested 
prior to, at the 
mid point and 
end of HBO 
therapy. 
Keratometry 
undertaken. 
Myopia as at days 1, 
10, 20. 
2 of the eight subjects showed 
increased myopia. 
Previous studies had 
examined patients 
who had 40 sessions 
of HBO; this study 
looked at patients 
receiving 20 sessions 
of HBO. 
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3. EFFECTIVENESS 
 
3.1 METHODS FOR REVIEWING EFFECTIVENESS 
 
3.1.1 Search Strategy 
 
Initial topic searches for the use of HBO, identified very limited randomised controlled trial 
(RCT) evidence on its efficacy. Therefore, a series of systematic searches have been 
undertaken to identify published evidence relating to trials and case series studies of the 
use of HBO and the health economics of HBO therapy. 
 
The searches involved subject searches of the following medical and health databases: 
MEDLINE; EmBASE; COCHRANE, and SCIENCE CITATION INDEX, together with 
examination of the relevant health technology assessment agency resources: such as web 
sites, booklets etc. 
 
3.2 RESULTS  
 
3.2.1 Quantity and Quality of Research Available  
 
Initial searching revealed a large number of research papers relating to hyperbaric oxygen 
for the prevention and treatment of ORN, wound healing and dental implants. Studies were 
limited to those reported in English on human patients.  
 
The presence of only a very small number of RCTs in the reported results of the studies 
substantially weakens the quality of evidence.  
 
3.2.2 Assessment of Effectiveness  
 
(a)  Treatment of Osteoradionecrosis 
 
Case Studies 
 
The evidence provided by case studies is summarised in Table 9. It comprises a relatively 
small number of retrospective case studies, published since 1975. Much of the work was 
carried out in the 1970s and 1980s. Due to the nature and incidence of the disease they 
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tend to comprise small numbers of patients over long time periods. Many of the studies 
suffer from inadequate detail on methodology and inconsistent endpoints.  
 
The evidence from these case studies does offer some support for the use of HBO in the 
management of ORN. Some cases of ORN may respond to conservative treatment.
37,38
 
However, where conservative treatment has failed, HBO, as an adjunct to antibiotic and 
surgical therapy, may offer additional benefits to some patients.
39,40,41
 However, the strength 
of the evidence is weakened by the lack of RCTs. 
 
Health Technology Assessment Reviews 
 
Two Canadian Health Technology Assessment reviews of hyperbaric oxygen treatment 
have been carried out. The conclusions are summarised below: 
 
Sheps British Columbia Office of Health Technology Assessment Discussion Paper
1
 
This paper concluded that 'Given the complexity of the post-radiation ORN from a 
physiological and clinical perspective, and since there would seem little else you could offer 
the patient, HBO may well be a useful adjunct in this situation'. The authors' review of the 
evidence concluded that HBO for ORN of the mandible did seem to have some support, but 
that further work comparing treatments, with and without HBO, was required. 
 
Mitton Health Technology Assessment Publication - Hyperbaric Oxygen Treatment in 
Alberta
42
 
This report considered the application of HBO for 12 conditions, one of which was ORN. It 
concluded that 'although results are promising, further studies are required to provide a 
clear picture of the effectiveness of HBO for this condition.' 
 
Other Reviews 
 
Myers and Schnitzer
43
 
Myers (Chairman of the Department of Hyperbaric Medicine at the Maryland Institute for 
Emergency Medical Services Systems) and Schnitzer report radiation necrosis as a 
condition for which HBO is known to be successful, referencing Greenwood and Gilchrist
44
 
and Marx and Ames.
27
 
 
Balogh and Sutherland
45
 
This review concludes that conservative management of ORN is recommended unless the 
disease is advanced or progressive. Treatment by HBO is 'complex and time-consuming 
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and results are confounded by the concurrent use of local antiseptic/antibiotic measures and 
surgery.' 
 
Grim et al.
46
 
This review reports on evidence from Marx
47
, Farmer
48
 and Davis
49
 and concludes that 'the 
role of HBO as an adjunctive therapy in the treatment and prevention of osteonecrosis has 
been impressively documented.' 
 
Myers and Marx
50
 
This is an overview of Marx’s work outlining the Marx Protocol and detailing the cost 
analysis of Marx and Johnson 1988.
51
 
 
Tibbles and Edelsberg
52
 
This is a review of the mechanisms of action and evidence of clinical efficacy. It concludes 
that the prevention and treatment of ORN is one of the uses of HBO for which the 'discovery 
of beneficial cellular and biochemical effects has strengthened the rationale for 
administering hyperbaric oxygen as primary therapy…' Osteoradionecrosis is listed as one 
of the diseases for which 'the weight of scientific evidence suggests that hyperbaric oxygen 
may be helpful'. 
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Table 9 (a) Evidence of the Effectiveness of HBO for the Treatment of Osteoradionecrosis  
 
 
Author, Date 
Country 
Aims of study Patient population Study design 
/ period 
Intervention Outcome measures Results Comments 
London et al.
53
 
 
1998 
USA 
Review use of HBO 
in management of 
ORN of the head 
and neck. 
16 patients with ORN. Retrospective 
study. 
HBO alone or 
HBO and 
surgery. 
Patient and physician 
grading scores. 
All patients showed clinical improvement with 
decreased pain following HBO therapy. 
 
 
Wong et al.
54
  
 
1997 
Canada 
To determine 
effectiveness of 
nonsurgical/ 
nonhyperbaric 
oxygen 
conservative 
management. 
Correctly define 
ORN. 
32 patients with 
mandibular ORN, seen 
between Aug 1960 and 
Sept 1995. Mean age 64, 
range 46-92. 
Retrospective 
records analysis. 
Conservative 
management 
and resection, 
HBO therapy or 
both were 
initiated in 
cases of pain, 
failure to 
respond to 
conservative 
measures and 
progressive 
deterioration. 
 2/32 died before final analysis; of those alive 
65.5% patients were spared resection, 48.3% 
had lesions resolved, 3.4% improved, and 
13.8% asymptomatically stabilized. 
Sequestrum production allowing ‘gentle’ 
removal predicted a more favourable clinical 
course when managed conservatively 
compared with nonsequestrating lesions 
(p<0.05). Of 11 patients receiving combination 
radiotherapy, 5 had resolution, 3 went on to 
resection and HBO, 2 had lesions stabilize 
and 1 died with ORN. Complete resolution 
48% of 29 patients. 
HBO is not 
universally 
applicable to all 
ORN cases for fiscal 
and physical 
limitations. 
Aitasalo et al.
55
 
 
1998 
Finland 
Evaluate 
effectiveness of 
surgical 
decortication and 
free periosteal 
transplantation 
combined with 
antibiotics as well 
as pre-and post-
operative HBO in 
treatment of ORN 
and chronic 
osteomyelitis 
(COM). 
69 patients: 36 patients 
with ORN, 33 patients with 
COM of mandible or 
maxilla. Aged 7 – 72, 
mean 54 yrs. 
Median follow-up time = 
34 months, min of 10 
months. 
1981-1998. 
Retrospective 
study. 
HBO and 
surgical therapy 
(decortication 
of affected 
bone). 
Periosteal 
transplantation 
and antibiotics. 
Symptom-free 
success rates. 
33 ORN patients (92%) and 26 COM patients 
(79%) remained symptom-free after first 
treatment period. 3 failed ORN patients were 
successfully treated with a free microvascular 
flap. The seven failed COM patients were 
retreated, and 5 of them have occasional 
clinical symptoms.  
A combination of 
HBO and 
decortication with 
periosteal grafting is 
successful treatment 
for ORN and COM. 
Combination used in 
study allowed HBO 
to be reduced, and, 
therefore, costs too.  
Thorn et al.
56
 
 
1997 
Denmark 
Measure effect of 
HBO on 
transmuscular 
oxygen tension in 
irradiated human 
oral muscosa. 
10 patients with 
mandibular 
osteoradionecrosis. 4 
women, 6 men. Aged 46-
72. 
Physiological 
study. 
HBO, three 
also had 
sequestrial 
surgery after 20 
'dives', one of 
which did not 
heal after that. 
Level of gingival 
surface transmucosal 
oxygen tension. 
Patients measured 
against 5 healthy 
control individuals. 
Transmuscosal oxygen (T.O.) tension 
increased significantly after 5 'dives'. P < .05 
compared with pretreatment values. After 30 
'dives', the increases were from a mean of 
50% to a mean of 86% of the T.O. tension of a 
normal healthy gingiva. Smallest increase was 
from 41%-69%. This patient did not heal after 
sequestromy. Maximal increase range was 
53% to 100%. 
Patients with 
subischaemic 
tissues, e.g. study 
pop. with post-
irradiation muscosal 
and osseous 
necrosis, may 
benefit from HBO. 
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Epstein et al.
38
 
 
1997 
Canada 
 
Assess long-term 
progress of patients 
who experienced 
ORN of the jaw. 
20 live patients (out of 
original 26 patients) with 
ORN of the mandible.  
Long-term follow-
up study of 
patients treated 
between 1975 
and 1988. 
 % resolved, chronic 
persisting (unresolved) 
or active progressive. 
Recurrence occurred in 10% of patients alive 
at end of 5 year follow-up 
60% (12/20) remained resolved 
10% (2/20) improvement in clinical staging 
20% (5 of 20) chronic persistent ORN  
(stage II). 
 
Paper supports 
treatment of chronic 
non-progressive 
ORN without HBO 
intervention. 
 
Wood and 
Liggins
41
 
 
1996 
UK 
 
Does HBO have 
role in management 
of ORN? 
 
 
12 episodes of ORN 
treated with HBO in 11 
patients over 8 years. All 
patients have previously 
received conservative 
treatment. 
 
Retrospective 
study. 
 
HBO – Marx 
Protocol. 
 
% cure rate. 
 
100% cure, with 83% of cases requiring 
surgery to remove necrotic bone. 
 
 
 
 
van 
Merkesteyn et 
al.
57
 
 
1995 
Netherlands 
 29 patients with ORN of 
the mandible, 26 of whom 
had previously received 
conservative treatment or 
surgery. 
Retrospective 
case study. 
HBO, surgical 
debridement 
and antibiotics 
in 27 of 29 
cases 
24 of 27 HBO 
patients : 30/10 
protocol. 
% resolved 
 
% patients 
experiencing loss of 
continuity of the 
mandible. 
69% (20 of 29) patients resolved 
Resection necessary in 23 patients 
31% loss of continuity. 
 
 
Mounsey et 
al.
58
 
 
1993 
USA 
To establish 
whether HBO is 
beneficial in 
management of 
ORN, and to define 
clearly the role in 
which HBO is most 
valuable. 
41 patients with 
mandibular ORN from 
1980 to 1985. 
Retrospective 
analysis. 
HBO in addition 
to a 
combination of 
oral hygiene 
regimens, 
dental therapy, 
antibiotics and 
surgery. 
Exposed bone, 
closure of fistulous 
tract, complete relief 
of symptoms, 
especially pain. 
83% of patients had significant improvement 
with HBO therapy, judged by at least 50% 
decrease in the size of exposing of fistuous 
tract, or complete relief of symptoms. 6 
patients (15% of 83 %) showed complete 
resolution of ORN. 17% of them did not 
benefit from HBO; all 7 patients had evidence 
of dead bone. Surgery was combined with 
HBO in 35 cases, 85%.  
HBO is of benefit. 
Cases of mild ORN 
will heal with HBO 
alone, severe cases 
require surgery to 
remove dead bone. 
Authors suggest 
regular follow-up, in 
order to detect ORN 
at time when HBO 
can arrest disease. 
McKenzie et 
al.
59
 
 
1993 
 
 
 26 patients with ORN of 
the mandible treated with 
HBO. 
 HBO.  69% (18 of 26) resolution of first episode of 
ORN. 
12% (3 of 26) improvement in staging 
19% (5 of 26) no improvement. 
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Marx and 
Johnson
30
 
 
1988 
The role of HBO in 
oral and 
maxillofacial 
surgery.  
268 patients with 
refractory ORN. 
Protocol for ORN, 3 
stages combining HBO 
and surgery. Over 8 yr 
period. 
 HBO and 
surgery. 
1. Freedom from pain,   
2. Retention/ 
reconstruction of 
mandibular continuity. 
3. Restoration of 
mandibular function 
and wearing of dental 
appliances, if required.   
4. Maintenance of 
intact mucosa and 
skin over the bone. 
196/268 which had been unresponsive under 
other institutions were resolved under this 
scheme.  
Resolution in Stage I for 38 (14%), in Stage 2 
48, (18%), Stage III 182, (68%). 
Not much more 
expensive compared 
to conventional 
practice when one 
looks at all hidden 
costs. Resolution 
rate is higher over 
years and remaining 
quality of life is 
higher. NB. HBO 
used in majority of 
cases where other 
treatments have 
already failed. 
Beumer et al.
37
 
 
1984 
USA 
 70 patients suffering from 
83 episodes of ORN, 
radiation-induced bone 
necrosis of head and 
neck, maxilla (5), 
mandible (78). 
11 yr. period, ending July 
1982. Follow-up for 1 yr. at 
least. 
 Saline 
irrigations, 
antibiotics, 
antiseptic/biotic 
dressings. If 
disease 
progressed, 
HBO and 
surgical 
sequestrec-
tomy. 
Healed, worse, 
mandibular resection 
necessary. 
22/83: postradication extractions. 19/83: 
periodontal disease. 17/83 preradiation 
extractions. Mandibular resection rate was 
44% in bone necroses where external 
radiation dose to affected bone exceeded 
7000 Rad. Overall mandible resection = 23/78. 
31 episodes healed, 15 were stable or 
improving with conservative treatment, 37 
patients required the more aggressive therapy. 
Of these 24/37 had HBO, 13/37 had radical 
resection.  
9 patients received HBO before and after 
sequestrectomy. Of these in 7/9 infection was 
controlled without loss of mandibular 
continuity. 4 patients had sequestrectomy 
without HBO; all 4 required resection of the 
mandible. 
HBO is useful 
adjunct to therapy, 
particularly if 
combined with 
surgical 
sequestrectomy, for 
large exposures 
extending beyond 
the mucogingival 
junction. 
Marx
39
 
 
1983 
USA 
Investigation into 
effect of HBO and 
combination of HBO 
and surgery. 
58 patients with refractory 
osteoradionecrosis.  
Investigatory 
HBO protocol 
based on patho-
physiology 
elucidated in 
previous report.  
3 Stages:  
I = HBO,  
II = surgery 
further HBO, 
III = surgery 
further HBO. 
HBO and 
aggressive 
surgery. 
Resolution criteria: 
1. Freedom from pain. 
2. Retention or 
reconstruction of 
mandibular continuity.  
3. Restoration of 
mandibular function.  
4. Maintenance of 
intact mucosa over all 
bone for length of 
follow-up min 18 
months.  
 
Resolution achieved in Stage I for 9 patients, 
15%. 8 patients in Stage II 14%, and 41 
patients in stage III 70%.  
41/58 required partial mandibulectomy. All 
discontinuous mandibles were reconstructed 
and function restored in all patients. 
HBO enhances healing, but without 
aggressive surgery will not resolve disease 
process alone, (only 15% responded in  
stage I). 
 
Results suggest 
HBO and surgery 
should be primary 
treatment. 
Need to get right 
timing, patient, 
disease state and 
combination of HBO 
and surgery. 
  31 
Davis et al.
49
 
 
1979 
Test HBO therapy 
as adjunctive 
therapy. 
52 cases radiation 
necrosis; 39 of head and 
neck, 23 ORN of 
mandible. 16 soft-tissue 
radionecrosis of head and 
neck. 
1-23 months 
follow-up so far, 
24 months follow-
up in total. 
HBO, (surgery 
and antibiotics). 
Wound healing 
enhancement. 
Arrested/ failed. 
22/23 ORN of mandible excellent initial 
response. 1-23 months, 17/20 arrested, 3/20 
failed. At 24 months 3/20 arrested. 15/16 soft-
tissue radionecrosis, good response.  
Recommend use of 
HBO as soon as 
possible after such a 
wound begins to 
deteriorate. 
Farmer et al.
48
 
 
1978 
Investigate effects 
of HBO therapy in 
management of 
radiation necrosis. 
13 cases of refractory 
mandibular radionecrosis. 
3 cases of head and neck 
radionecrosis. 3 others: 
radionecrosis of foot, hip 
and vagina. Age range 43-
68.  
Pilot study 
Follow-up 1-27 
months. 
HBO. Improvement in: Pain, 
Soft tissue disease,  
X-ray changes. 
Of 13 cases: Soft tissue disease: 7 cases 
complete healing, 11-27 months. Transient 
healing in 3, moderate-marked improvement 
in 3. Marked pain relief in 6, moderate in 4, 
slight in 1. Radiographic improvement, slight 
to moderate in 10, none in 3. 3 cases 
head/neck, significant improvement in lesions. 
Extra 3 only good results in vagina case. 
HBO is beneficial 
adjunctive treatment 
in radiation necrosis 
of bone and soft 
tissue, particularly of 
head and neck. 
Although potentially 
expensive and 
complex. 
Hart and 
Mainous
60
 
 
1976 
Investigate 
treatment of 
radiation necrosis 
with HBO. 
69 patients with radiation 
necrosis: of mandible 46, 
of chest 6, of pelvis and 
lumbar areas 6, CNS 6, 
larynx 5.  
Jan. 1969  
through Aug. 
1975. 
HBO (surgery 
and antibiotics). 
1. Intractable pain        
2. Exposed bone,              
3. Orocutaneous 
fistula,  
4. Pathological 
fracture. 
Mandible 46 patients: 2% had 1 only, 43% had 
1 and 2, 13% had 1, 2 and 3. 22% had 1, 2 
and 4. 20% had 1, 2, 3 and 4. Chest wall: all 
grafts healed primum. Pelvis and Lumbar.  
HBO supports the 
healing of ischemic 
tissues, however, it 
does not relieve 
clinician of necessity 
of surgery or admin. 
of antibiotics.  
Mainous and 
Hart
61
 
 
1975 
 
 14 patients intractable 
ORN of mandible.  
Follow-up 1-8 yrs. HBO. Intractable pain and 
exposed bone. 
All 14 healed. Very favourable 
changes in the 
healing 
environment. 
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Table 9  (b) Evidence of the Use of HBO in the Prevention of Osteoradionecrosis  
 
 
Author 
Date  
Country 
Aims 
Of  
Study 
 
Patient  
Population 
Study 
Design 
Intervention Outcome  
Measures 
Results Comments 
Maxymiw et al.
62
 
 
1991 
Canada 
To assess surgical 
techniques for the 
management of post 
radiation dental 
extractions without 
HBO. 
72 patients who 
had extractions 
after head and 
neck radiation 
therapy. 
Prospective. Prophylactic antibiotic 
(Penicillin V) coverage 1 
hour prior to surgical 
procedure and then 600 
mg qds for 1 week. Low 
concentration local 
anaesthetic (prilocaine) 
atraumatic surgical 
technique. 
Healing; 
No ORN. 
No ORN  
Stofka and Liang
63
 
 
1994 
USA 
Review and case 
report. 
15 year old girl. Case report. HBO prior to dental 
treatment. 
 Uneventful recovery post 
dental treatment. 
Recommends HBO in 
post irradiated patients 
prior to dental treatment. 
Kraut
64
 
 
1985 
USA 
To assess the 
prophylactic use of 
HBO. 
3 cases - male. Case Study. Prophylactic HBO prior 
tooth extraction. 
Healing without 
ORN. 
Healed – no complications.  
Marx et al.
65
 
1985 
USA 
To evaluate the use of 
HBO in the prevention 
of ORN. 
74 patients who 
had an indication 
for removal of one 
or more teeth from 
a segment of 
irradiated 
mandible. 
RCT. HBO  
Compared with 
prophylactic penicillin. 
Development of 
ORN; 
3 weeks; 
6 months. 
2 patients (HBO Group) 
developed ORN (5.4%). 
11 patients (non HBO) 
developed ORN (29.9%). 
Not clear whether 
observers were blinded. 
The study is now ‘out of 
date’ since the incidence 
of ORN has now fallen 
dramatically. 
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Table 9  (c) Evidence of the Effectiveness of HBO for Implants 
 
Author 
Date 
Country 
 
Aims of study 
 
Patient 
Population 
 
Study Design 
 
Intervention 
 
Outcome Measures 
 
 
Results 
 
Comments 
 
Granstrom et 
al.
66
 
 
1999 
Sweden 
 
Report of 78 cancer 
patients. 
 
 
78 cancer patients  
rehabilitated using 
osseointegrated 
implants. 
 
Case control 
Study. 
 
 
Irradiated non- 
irradiated,  
irradiated and 
HBO. 
 
 
Review of success of 
individual implants. 
 
 
In irradiated-only patients, 
implant failure was 54%. 
In non-irradiated patients it was 
14%. 
In irradiated and HBO patients, it 
was 8%. 
 
 
This study showed that although 
implant insertion in irradiated bone is 
associated with a higher failure rate, 
HBO treatment can reduce the 
failures.  
 
 
Jisander et 
al.
67
 
 
1997 
Sweden 
 
 
 
 
 
Report of 17 oral 
cancer patients. 
 
17 patients with 
oral cancer were 
treated by 
irradiation.  
Implants were 
placed for 
rehabilitation. 
 
Case control 
study. 
 
HBO in 7 patients 
All received implants. 
8 patients received 
more than 50 Gy and 
9 less than 50 Gy. 
 
Patient follow-up for 
average of 21 
months. 
 
103 implants were placed. There 
was a 92% survival rate in the 
maxilla and 97% in the mandible. 
 
The paper concluded that the risk of 
implant failure might be reduced by 
adjunctive HBO treatment. It also 
concluded that the successful 
placement of implants in patients 
receiving more than 50 Gy was 
probably the result of HBO therapy. 
 
Marker et al.
68
 
 
1997 
Denmark 
 
 
 
 
 
 
 
Report of 12 oral 
cancer patients. 
 
12 patients with 
oral cancer 
involving the 
mandible were 
treated by radiation 
and/or surgery. 
19 implants were 
placed. 
 
Case control 
study. 
 
HBO was not used. 
Radiation dosages of 
40-50 Gy were used. 
 
Patient follow-up 
from 14 to 44 
months. Implant 
success was 
determined. 
 
All 19 implants were successful, 
and osseo-integrated without 
signs of infection or osteoradio-
necrosis. 
 
The paper concluded that patients who 
have been irradiated can successfully 
receive titanium implants. 
The use of HBO appears unnecessary 
with radiation doses of up to 50 Gy. 
 
Arcuri et al.
69
 
 
1997 
U.S.A. 
 
 
Report of 4 oral 
cancer patients. 
 
4 patients with oral 
cancer involving 
the mandible. 
18 implants were 
placed. 
 
Retrospective 
follow-up study. 
 
HBO was used for all 
patients. 
No radiation dosage 
was given. 
 
Patient follow-up 
from 1-5 years. 
 
17 implants were successful. 
One failed to show osseo- 
integration. 
 
This small study suggests that titanium 
endosseous implants placed in 
previously irradiated mandibles in 
conjunction with HBO therapy may be 
successful. Further research is 
required. 
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Esser and 
Wagner
70
 
 
1977 
Germany 
 
 
Report of 221 
implants in 
mandibles, following 
oral cancer. 
 
60 patients with 
oral cancer 
involving the 
mandible between 
1985 and 1995. 
 
Retrospective 
follow-up study. 
 
HBO was not used 
for any patient. 
Radiation dosages of 
60 Gy were given. 
 
Patient follow-up up 
to 5 years. 
 
2 patients suffered osteo-
radionecrosis and 1 soft tissue 
necrosis. 
18 implants failed to osseo-
integrate and 15 lost osseo-
integration over a 30 month 
period. 
 
The report considered that the 
incidence of osteoradionecrosis was 
low. The use of HBO had not been 
considered then. 
The report speculated that the use of 
HBO could prevent soft-tissue necrosis 
or improve healing. 
In patients at risk of 
osteoradionecrosis, HBO could be 
useful. 
 
 
Taylor and 
Worthington
71
 
 
1993 
USA 
 
 
 
Report of 21 
implants placed in 4 
irradiated patients. 
 
 
4 patients with oral 
cancer treated by 
surgery, and 
irradiation. 
 
 
Case control 
Study. 
 
 
HBO in 3 patients. 
Radiation doses of 
more than 60 Gy 
were used. 
 
 
Patient follow-up 3-7 
years to review 
success of implants. 
 
 
No implants lost. The patient 
without HBO experienced soft-
tissue breakdown, but healed 
and implants successful. 
 
 
 
 
A clear effect of HBO was not 
demonstrated in this small study. The 
study did demonstrate the successful 
placement of implants in mandibles 
which were irradiated with doses of 
more than 60 Gy. 
 
 
 
 
  35 
Table 9 (d)  Review of Evidence of the Effectiveness of HBO for Wound Healing 
 
 
Author 
Date 
Country 
 
Aims of Study 
 
Patient Population 
 
Study Design 
 
Intervention 
 
Outcome 
Measures 
 
 
Results 
 
Comments 
 
Neovius et 
al.
72
 
 
1997 
Sweden 
 
Review of the 
literature and a 
report of 15 
consecutive 
patients. 
 
15 patients with soft-tissue 
wounds without signs of 
healing after surgery in 64 
Gy irradiated head and neck 
regions. 
 
Consecutive 
retrospective 
study. 
 
HBO and adjuvant 
therapy. 
 
Follow-up at various 
intervals. 
 
In HBO group, 12 of 15 patients 
healed completely, 2 partially 
within 1-5 months, 1 did not 
heal. 
 
In non-HBO group, 7 of 15 
patients healed, 2 had massive 
acute bleeding, 5 required 
further surgery. 
 
 
 
The study was on 15 irradiated ENT 
patients. 
None had osteoradionecrosis of the 
mandible. 
 
This small study tends to support the 
role of HBO in soft-tissue wound-
healing. 
 
Kindwall
29
 
 
1993 
USA 
 
A study of 
incidence of 
wound dehiscence 
with and without 
HBO. 
 
160 patients divided into 2 
groups of 80. 
 
Randomised 
prospective 
controlled trial. 
 
HBO. 
 
Follow-up at 3 
weeks. 
 
Control group had 15% minor 
and 33% major wound 
dehiscence. 
In the hyperbaric group there 
was 7.5% minor and 3.5% 
major wound dehiscence. 
 
 
 
The study relates only to soft-tissue 
flap surgery, but demonstrates a 
significant effect of HBO therapy on 
soft tissue wound healing. 
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 (b) Prevention of Osteoradionecrosis 
Evidence relating to the efficiency of HBO for the prevention of ORN is equivocal. There is a 
lack of appropriate RCTs which makes assessment of the use of HBO for the prevention of 
ORN difficult. Those studies, which indicate a positive role for this therapy, tend to have 
taken place in the 1980s. The only RCT, undertaken by Marx et al.
65
 compared two groups 
of patients, one having HBO and one having penicillin before their extractions. The study 
found a significant reduction in ORN in the HBO group from 29.9% to 5.4%. Clayman
19
 
notes that there is a particularly high overall rate of ORN, 35%, in these patients. The 
applicability of this study to the general population of patients in whom the ORN rate is less 
than 6% is certainly open to question.  
A more recent study
62
 has shown that an atraumatic surgical technique, combined with 
prophylactic antibiotics and lowered dose of radiotherapy significantly reduces the incidence 
of ORN after surgery to the irradiated mandible/maxilla. If low rates of ORN can be achieved 
without HBO, the use of HBO is unlikely to be cost-effective. 
 
(c)  Dental Implants 
 
The absence of any RCTs in the reported results of the studies weakened the evidence, but 
the studies reported gave a consistent result with respect to levels of radiation given. The 
evidence from the clinical cases reflected the theoretical benefits of HBO in the regeneration 
of bone, necessary for successful osseointegration of titanium implants. A RCT is needed to 
establish conclusively the level of radiation beyond which HBO therapy would be necessary 
to ensure successful osseointegration. 
 
(d) Wound Healing 
 
Most of the studies on wound healing related to areas unconnected with the head and neck, 
or were covered in the other three parts of this study. Only a small number of studies related 
specifically to soft-tissue wound-healing following cancer of the head and neck. The study 
by Marx
73
 provided evidence at the RCT level involving 160 patients (80 HBO, 80 control) 
that there were significantly fewer or less severe complications of wound healing in the HBO 
group. Greenwood and Gilchrist
44
 and Neovius et al.
72
 reported evidence from small case-
controlled studies in support of the hypothesis that HBO therapy had a clinically significant 
effect on initiation and acceleration of healing processes in irradiated soft tissues. Further 
study is required to establish the efficacy of HBO in soft tissue wound healing following 
irradiation of the mandible. 
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The evidence supports the use of HBO in the treatment of refractory anaerobic or mixed 
bacterial soft tissue infections. HBO therapy should be integrated within a treatment protocol 
comprising adequate surgical and antibiotic therapy. 
 
3.2.3 Summary and Conclusions  
 
The value of HBO therapy for the treatment of ORN remains controversial. There are a 
number of studies which lend support to the use of HBO. However, these are generally 
retrospective case studies of small numbers of patients over long time periods. They are 
often poorly described in terms of methodology, making it difficult to draw any clear 
conclusions. In addition, many of the studies date back to the 1970s and 1980s. Since this 
time many factors have changed, including improved dental care and follow-up and more 
efficient use of radiation, resulting in a decline in the incidence of ORN.
20
  
  
Treatment protocols based on careful wound care and scrupulous surgical technique, such 
as that proposed by Schwartz
74
, suggest that ORN can often be successfully managed 
without HBO. Schwartz
74
 comments that he is aware of 'numerous ORN cases, treated with 
HBO protocols, who have failed to do as well as Marx’s patients' and suggests the quality of 
the surgery, rather than HBO, may be the key. Maxymiw
62
 reported no cases of ORN 
among 72 patients based on the use of nonlidocaine local anaesthetics, antibiotics and 
conservative surgery following dental extraction. However, these protocols are also based 
on empirical evidence alone.  
 
Conservative measures of therapy appear to control a reasonable proportion of bone 
exposures, particularly in patients receiving less than 65 Gy to the affected bone.
37
 It seems 
likely, however, that there is a sub-set of patients for whom HBO offers benefits. It is not 
possible to define precisely the characteristics of the patients who make up this sub-set. 
 
There is an urgent need for data to support the use of HBO as a treatment modality which 
prolongs implant survival. 
 
In conclusion, the existing evidence does not provide a clear direction for policy. Further 
studies are required to provide a more definite picture of the effectiveness of HBO.  
 
A properly designed clinical trial would answer a number of important questions: 
 
1.  Does the use of HBO result in improved outcomes? 
2.  For which sub-groups of patients? 
  38 
 3.   What is the recommended protocol - how many 'dives' and at what pressure? 
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4. ECONOMIC ANALYSIS  
 
4.1 METHODS FOR ECONOMIC ANALYSIS  
 
A 'typical' health authority would expect to see less than 20 patients per year with oral 
cancer. Local clinical opinion suggests that around 50% of these patients receive 
radiotherapy, although this figure may vary on a local basis. Incidence rates of ORN have 
declined as a result of more efficient use of radiation and improved surgical techniques and 
dental care. The current incidence of ORN is not known with certainty, but is assumed to be 
around 5%. Therefore, the number of patients likely to experience ORN at any time after 
radiotherapy is expected to be less than one per year per health authority. 
 
The use of HBO prior to implants is the most likely area of future demand for HBO. It is 
estimated that only around 5 - 10% of oral cancer patients who have radiotherapy currently 
receive implants, although this figure may vary nationally. Therefore, a 'typical' health 
authority would currently expect to have only one or two oral cancer patients per year 
receiving implants. Given that up to 25% of oral cancer patients who have radiotherapy may 
benefit from implants, this number could rise to around five patients per health authority. 
There is also a pool of patients, of unknown size, treated in earlier years who might benefit 
from implants. (Brook - Personal Communiation, 2000). 
 
4.1.1 Treatment of ORN 
 
The resource implications in relation to the treatment of ORN are, therefore, small and likely 
to remain so.  
 
A detailed cost-benefit analysis has not been undertaken. The results of two previously 
reported non-UK cost-effectiveness analyses of the treatment of ORN are summarised and 
reviewed. 
 
Dempsey et al.
18
 Cost-effectiveness Analysis of Hyperbaric Therapy in 
Osteoradionecrosis  
 
The paper by Dempsey et al. presents cost-effectiveness analysis of hyperbaric therapy 
from a societal perspective. The aim is to determine whether hyperbaric therapy is more 
cost-effective than the conservative therapy treatment for osteoradionecrosis. The 
incremental costs and effects of HBO are compared with the more traditional treatment of 
conservative therapy. The analysis supports the cost-effectiveness of HBO. The 
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methodology employed appears reasonable. However, the results are highly dependent on 
the length of stay assumptions used for which no references are provided. In addition, the 
100% success rate for HBO treatment reported in this study is not replicated in other HBO 
studies. 
 
Methodology 
Dempsey assesses the cost-effectiveness of HBO by comparing 21 HBO patients with 21 
hypothetical ‘conservative therapy’ patients. The costs and effects of the hypothetical group 
were calculated based on the expected outcome obtained from the literature. 
 
Dempsey defines two types of treatment, 'conservative therapy' and the Marx University 
HBO protocol. The paper identifies five steps used in conservative therapy. Step 1 involves 
the patient avoiding local irritants; step 2 involves the irrigation of the area with a variety of 
agents; step 3 involves the prescription of antibiotics; step 4 involves superficial 
sequestrectomies and reconstructive surgery (step 5) is the last resort. Dempsey states that 
'the resolution rate after the first four steps of this therapy ranges from 8% to 75%.' 
Reconstructive surgery, Step 5, only has a reported success rate of 66%.  
 
The Marx University HBO protocol combines the treatment of HBO with specific surgery. 
Marx claims 100% success rate. There are four stages in the Marx University HBO 
treatment. All patients except those suffering from orocutaneous fistulae, pathological 
fracture and extensive bone resorption enter stage 1. However, the HBO protocol was 
modified in this study to allow the physician to use his discretion.  
 
Stage 1 involves 30 HBO exposures at 2.4 atmospheres for 90 minutes each. Saline rinses 
are used to maintain wound care. If the patient shows signs of clinical improvement he/she 
undergoes 10 additional exposures. If the patient shows no signs of improvement he/she is 
considered a non-responder and advances to stage 2. 
 
Stage 2 involves a local surgical debridement. If the patient shows signs of improvement 
he/she undergoes 10 additional exposures. If no improvement is evident, the patient 
advances to stage 3 as a non-responder.  
 
Stage 3 involves a partial jaw resection and 10 additional HBO exposures. Patients then 
advance into stage 3-R which involves a bony reconstruction, 10 additional HBO 'dives' and 
eight weeks' jaw fixation. 'If further surgery is not required, the patient may enter prosthetic 
rehabilitation one month after fixation is released.'  
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The costs of the 21 HBO patients were compared to the costs of the 21 hypothetical 
‘conservative therapy’ patients. Data presenting the costs of HBO were obtained from the 
Hamilton Civic Hospital, Ontario and from the relevant literature. Costs were presented in 
1995 Canadian Dollars and were calculated for medications, sequestrectomy, dental 
extractions, out-patient visits, hyperbaric therapy, in-patient days and reconstructive surgery. 
Indirect costs such as lost earnings were not included in the analysis.  
 
Results 
In the HBO group, 57% healed during stage 1; 34% healed during stage 2 and 9% healed in 
stage 3. In the hypothetical ‘conservative therapy’ group, 65% of patients healed before 
reconstructive surgery, 23% healed after reconstructive surgery and 12% remained 
unhealed.  
 
The cost per patient of treating the 21 hypothetical patients by conservative therapy was 
$63,211. This figure includes the cost of one round of Marx therapy for the three patients 
who were not cured by conservative means. The cost per patient of treating the HBO 
patients was $10,064. The cost of HBO was, therefore, less expensive. In addition, three 
more cases were resolved than with conservative therapy. Patients who underwent HBO 
treatment also enjoyed greater pain reduction and increased sleep while requiring fewer 
narcotics.  
 
A sensitivity analysis was performed to address any problems concerning the validity of the 
data collected from the hospitals or from the literature. The variables, conservative therapy 
effectiveness, cost per in-patient day and the cost of reconstructive surgery were varied in 
the sensitivity analysis. The sensitivity analysis suggested that the key cost driver for both 
treatments of osteoradionecrosis is the number of days each patient spends in hospital.  
 
 
Marx and Johnson - Problem Wounds in Oral and Maxillofacial Surgery. The Role of 
HBO
51
  
 
This study reports on the cost of 300 osteoradionecrosis patients in America. Once again, 
the analysis concludes that HBO is the cheaper treatment. However, the results should be 
viewed with caution. The results are based on a study of patients treated in the early 1980s. 
The use of a 100% successful treatment rate for HBO and 8% for conservative treatment 
are not representative of the range of evidence available, and strongly influence the results 
in favour of the HBO option. The evidence of healing as a result of 'conservative treatment' 
of ORN of the mandible was reviewed by Clayman 1997,
75
 who reported healing in 58.7% of 
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cases. Clayman 1997
75
 reported that the average effectiveness of HBO from a range of 
studies was around 80%. 
 
Methodology 
Costs were calculated by the addition of the total course of treatment, all office visits, 
hospital care, surgery, medication and hyperbaric oxygen. This total was then normalised to 
the average prevailing fee. Indirect costs such as lost earnings were not included in the 
calculation of total costs. 
 
Results 
Marx and Johnson state that, in 1985, the average 1-year cost of treating 
osteoradionecrosis by ‘conservative therapy’ was $31,000. As only 8% resolved their 
disease in the first year, treatment continued for several years in most cases. The average 
total cost of treating osteoradionecrosis by conservative therapy is $102,000. (This figure 
could be even larger, as most of those not treated may have left the institutions reviewed 
and gone on to accumulate costs elsewhere.) 
 
The 1-year cost of treating osteoradionecrosis by HBO without surgery was calculated at 
$20,000. However, as 83% of cases required retreatment, the total cost of treatment rose to 
$62,000.  
 
The average 1-year cost of treating osteoradionecrosis with the Marx University protocol is 
$35,000. The resolution rate for this type of treatment is given as 100%. This suggests that 
it is, in fact, cheaper, as the total cost remains the same as the 1-year cost. This form of 
treatment also reduces pain and improves quality of life. Narcotics dependency is also 
reduced by this form of treatment. 
 
The 1-year cost of treating osteoradionecrosis by Marx’s protocol, but in a private practice, 
was estimated at $32,000. Again, a 100% resolution rate yields a total cost equal to the 1-
year cost. 
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Discussion of Non-UK Cost-effectiveness Studies 
 
The two studies demonstrate that prolonged 'conservative treatment' may be an expensive 
option. However, it cannot be concluded that all patients with ORN should be treated with 
HBO. Some patients respond well to conservative treatment and for these patients the use 
of HBO is not necessary. The use of HBO may be appropriate for a sub-group of patients 
who do not respond to conservative treatment. 
 
4.1.2 Prevention of ORN 
 
Many reviews have reported a high incidence of ORN after pre-radiation therapy extraction 
and post-radiation therapy extractions. Marx et al.
65
 recommended the use of HBO 
prophylactically before postradiation dental extractions. However, since this time the 
incidence of ORN has declined as a result of the more efficient use of radiation and 
improved surgical techniques and dental care, reducing the justification for prophylactic 
treatment.  
 
Two reviews have considered more recently the management of dental extractions in 
irradiated jaws. Clayman
19
 argued in favour of a protocol without HBO, whilst Lambert et 
al.
76
 argued in favour of a protocol with HBO. Neither of the reviews provides a detailed 
cost-effectiveness analysis.  
 
Clayman
19
 
 
This review considers whether the use of adjunctive HBO is justified before extracting teeth 
in irradiated mandibles. It examines the literature for evidence on the incidence of ORN, the 
success rates of conservative therapy, and the likelihood of one of the most severe 
complications of ORN, loss of continuity of the mandible. It concludes that, given declining 
rates of ORN and the relatively low rates of loss of continuity of the mandible, the evidence 
does not support the mandatory use of HBO before removing teeth in irradiated mandibles.  
 
Lambert
76
 
 
This paper argues that HBO should be used prophylactically for all patients requiring dental 
extraction on the basis that the cost of treating ORN is extremely high. In severe cases of 
ORN which may result in a pathologic fracture of the mandible, these costs may include 
HBO, partial mandibular resection, myocutaneous flap resurfacing of the neck and floor of 
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the mouth, and bone and skin grafting. Patients are likely to experience severe pain, long 
periods of hospitalisation and multiple surgical episodes. 
 
Modelling of Cost-effectiveness of the Prevention of ORN 
 
Modelling work has been undertaken to provide a crude indication of the cost-effectiveness 
of HBO in the prevention of ORN following dental extractions. The data on which these 
calculations are based is severely limited. The figures generated are intended to illustrate 
broad orders of magnitude only. 
 
Assumptions 
The following assumptions have been made: 
 Patients who undergo dental extractions following radiotherapy can follow one of two 
pathways: either they receive a course of HBO prior to the extractions or they undergo 
the extractions without additional intervention.  
 The incidence of ORN following extraction is 5.8%. 
 The effectiveness of HBO in the prevention of ORN is 80%. 
 The cost of HBO is £3,150, the current cost of treatment at the Diving Disease Research 
Centre in Plymouth. 
 Patients who develop ORN fall into two groups: group A patients are treated 
successfully by a single course of HBO, group B patients progress to the 'worst case' 
scenario. The worst case scenario is that the patient develops ORN and suffers a 
pathological fracture of the mandible. The patient suffers from constant pain, discharge 
and inability to take anything by mouth.  
 For patients who develop ORN, the probability of advancing to the worst case scenario 
is 55%.  
 The cost of treating the 'worst case' patients is not known with any degree of certainty. It 
is assumed that patients, at a minimum, will require HBO treatment (£3,150) and 
surgery (approx. £15,000), at a minimum total cost of approximately £20,000. These 
patients will be very ill and, therefore, will also require other medication and additional 
hospital care.  
 
Based on these assumptions, approximately five patients in a 'typical' health authority of 
500,000 will require dental extractions. If these patients follow the HBO pathway, the cost of 
the treatment is dominated by the cost of HBO treatment (around £14,500). The number of 
patients developing ORN is extremely small (less than one patient every 10 years) and, 
therefore, associated costs are negligible. If these patients follow the non-HBO pathway, the 
number of patients developing ORN is higher but still small (one patient every four years). It 
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is assumed that 55% of these patients develop the worst case scenario (approximately one 
patient every eight years). The relative cost of the HBO and non-HBO options is dependent 
on the cost of treating the worst case scenario. At a cost of £20,000, the expected cost per 
annum of the HBO pathway is four times that of the expected cost of the non-HBO pathway. 
The cost of treating the worst case scenario would need to be £100,000 for the cost of both 
options to breakeven. 
 
Sensitivity Analysis 
Due to the uncertainty surrounding the value of the parameters used in the modelling, a 
number of sensitivity analyses were undertaken. The impact of the sensitivities on the 
breakeven cost of the treatment of the worst case scenario is shown in Table 10. 
 
Table 10 The Breakeven Cost of the Treatment of the ORN (Worst Case Scenario) 
under Different Assumptions 
 
Basecase and Sensitivities Breakeven 
Cost 
 
Basecase   
      
 
 £100,000 
Sensitivities  
(a) Incidence of ORN: 29.5% without HBO, 5.4% with HBO  £17,500 
(b) Probability of patients progressing to worst case scenario: 
                         100% without HBO , 100% with HBO 
                         100% without HBO , 0% with HBO  
 
 £70,000 
 £55,000 
(c) Effectiveness of HBO:  
                          100% 
                            50% 
 
 £95,000 
 £127,500 
 
       
(a) The Incidence of ORN 
 
The reported incidence of ORN varies widely. Marx et al. reported the incidence of ORN to 
be 29.5% in patients without HBO and 5.4% in patients with HBO.
65
 This alters substantially 
the expected costs. The breakeven cost of treatment of the worst case scenario would be 
approximately £17,500. However the incidence rate of 29.5% appears to be extreme, with 
most recent estimates falling well below this value. In fact, Maxymiw et al. reported no cases 
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of ORN among 72 patients following dental extraction.
62
 The lower the incidence of ORN, 
the higher the cost of treating the worst case ORN scenario needs to be to make the HBO 
option cost-effective. 
 
(b)  The Probability of the Patients who Develop ORN Progressing to the Worst Case 
Scenario  
 
If the proportion of the patients with ORN who progress to the worst case scenario is 
assumed to be 100% for both HBO and non-HBO patients, the cost of the worst case 
scenario needs to be around £70,000 for the HBO option and non-HBO option to break 
even. It is likely that the probability of HBO patients developing the worst case scenario is 
lower due to revascularisation of the irradiated tissue. However, the exact difference is 
difficult to estimate. If it is assumed that the proportion of the HBO patients with ORN who 
progress to the worst case scenario is 0%, whilst the proportion of non-HBO patients 
remains at 100%, the breakeven cost is approximately £55,000. 
 
(c) The Effectiveness of HBO 
 
Assuming the effectiveness of HBO is 100% makes little difference to the expected cost of 
the HBO option. The breakeven cost of treatment for ORN would be £95,000. If the 
effectiveness of HBO was reduced to 50% the breakeven cost of treatment would be 
£127,500. 
 
This analysis suggests that the cost of treating the worst case scenario must reach 
£100,000 per patient in order for the option of offering HBO to be less expensive. Initial 
estimates of this cost suggest that it is unlikely to be high. However, more detailed evidence 
on these costs would be useful. This analysis does not take account of the quality of life of 
patients with ORN. These patients are in considerable pain, are unable to take anything by 
mouth and their quality of life is severely impaired. The addition of quality of life information 
would be useful in the debate. 
 
4.1.3 Wound Healing 
 
It is not possible to estimate the number of oral cancer patients who receive HBO for wound 
healing, but numbers are expected to be small. No analysis has been undertaken. 
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4.1.4 Dental Implants 
 
The use of HBO may reduce the proportion of implants which fail. Granstrom et al.
66
 showed 
that the use of HBO resulted in a significant reduction in the number of implants lost: 
 
 Irradiated jaw with no HBO    53.7% of implants lost 
 Irradiated jaw with HBO    8.1%% of implants lost. 
 
The cost of HBO treatment varies according to treatment location from £500 for patients 
receiving treatment at local chambers run by the MS society, to £4,500 for patients receiving 
treatment at Peterborough. 
 
Cost savings resulting from the reduction in implant failures include the additional resources 
used as a result of implant failure. If the implants fail, a patient is likely to have one or two 
operations under local anaesthetic and around 12 out-patient visits. The quality of life for the 
patient is obviously reduced. Patients who develop ORN suffer from a high degree of pain. 
Additional costs to them include social costs of pain, analgesic dependence and loss of 
productivity. 
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5. IMPLICATIONS FOR OTHER PARTIES  
 
5.1 QUALITY OF LIFE 
 
The role of HBO in the treatment or prevention of osteoradionecrosis in the mandible is 
important because of the characteristics of the disease itself. Although mandibular 
osteoradionecrosis was originally viewed as infected osteomyelitis secondary to radiation, 
Marx
39
 showed it to be an aseptic necrosis. Nevertheless, it is an unpleasant disease with 
marked necrosis of the bone of the mandible, often leading to pathological fractures. Often 
these fractures cannot heal without surgical intervention. The patient suffers protracted pain 
and disfigurement. In addition, soft tissue radionecrosis can be dangerous when the 
possibility of erosion into the carotid artery exists.
29
 Every effort should be made to prevent 
the development of osteoradionecrosis.  
 
Eighty-nine per cent of all trauma-induced osteoradionecrosis of the mandible is caused by 
tooth extraction in the radiated jaw.
29
 (The proportion of trauma-induced ORN relative to 
non-trauma-induced ORN is not known) Therefore, it is commonplace to extract all doubtful 
teeth in the site of the radiation, and to extract sound teeth where the condition of the 
patient is such that good oral hygiene could not be relied on to keep those teeth healthy. If 
HBO could reduce the necessity for tooth extraction in the years following radiation, more 
teeth could be preserved. This is a clear benefit for the patient, as sound natural teeth are 
far more efficient than the most perfectly-fitting dentures. Kindwall
29
 has also proposed that 
the extraction sockets in irradiated mandibles do not remodel as they do in the non-
irradiated mandible, leaving sharper edges on the alveolar ridge. This can cause problems 
for subsequent denture-wearing. 
 
Similarly, restoration of the irradiated mandible with titanium osseointegrated implants is an 
important issue in the quality of life. Successful placement of functional implants allows a far 
superior restoration of lost tooth tissue than does conventional dentures. If HBO can 
increase measurably the success rate for osseointegrated implants, then it can contribute 
positively to an increased quality of life for the patient. Failed implants can jeopardise a fixed 
prosthesis or bridge which affects the whole jaw and, thus, reasonable mastication for the 
future. 
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5.2 FINANCIAL IMPLICATIONS FOR PATIENTS AND OTHERS 
 
It is obvious that HBO must be supplied from purpose-built equipment. This can be in large 
dedicated centres, such as the Diving Diseases Research Centre in Plymouth, or at one of 
the numerous facilities in cities and large towns run by the Multiple Sclerosis Therapy Trust. 
The direct costs for both the patient and the NHS differ for each type, and these have been 
shown elsewhere. The indirect costs for the patient are concerned with the amount of time 
required for therapy. A typical protocol for HBO, developed by Marx, is the 20/10 ratio, 
involving in total 30 'dives' of approximately 90 minutes each. It is usual to undergo one 
'dive' per day, so the patient must be available for 30 days, in two blocks. If the patient is 
employed, this could lead to considerable loss of income, apart from the travel and 
subsistence costs. In addition, if they are sent to a remote site, even if the NHS pays for the 
bed and breakfast accommodation, it is still a greater expense to feed oneself away from 
home. These factors must be considered in the choice of HBO facility to which the patient is 
referred and, indeed, if the therapy is necessary, rather than just preferable. 
 
5.3 ETHICAL ISSUES 
 
The effectiveness of HBO in the applications mentioned in this paper has ethical 
implications. If the therapy is clearly effective in its described role, then it would be unethical 
not to provide it in those circumstances. Similarly, if it were not effective, it would be 
unethical to prescribe it routinely for all patients, as it has financial, time and other 
constraints, which would be wrong for a patient to bear if he/she cannot benefit. 
 
There is another ethical issue in the use of a RCT to determine exactly which patients would 
benefit from the therapy. Many people have called for this as a gold-standard in evidence 
(Schwartz - Personal Communication 2000). Whilst it would be invaluable for putting the 
case for HBO beyond dispute, the ethical issue of denying a treatment, believed by many, 
and established in a number of case-controlled studies, to be effective in the prevention and 
treatment of osteoradionecrosis, is problematical. It is small wonder that no-one seems 
willing to run such a trial at present. 
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5.4 SOCIAL AND LEGAL IMPLICATIONS 
 
The social implications of HBO use are as described above - cost, inconvenience and time 
for therapy, set against possible protracted pain, jaw fracture, additional surgery and 
diminished quality of life if not used. The balance must be found between the two, so that a 
protocol can be developed and accepted whereby those patients who would clearly benefit 
from HBO therapy, and only those, receive it. 
 
The legal implications are not so clear. Research in the Trent Region has shown, as 
reported in this paper, that only a small proportion of head and neck surgeons appear to 
prescribe HBO. Therefore, it cannot be accepted yet as a routine procedure. To the 
knowledge of the authors, the position of a Trust, Health Authority or Health Board denying 
such therapy to a patient has not been tested in the U.K. courts. However, as the use of 
HBO therapy continues to increase, it may in time be seen as a patient’s right. Such a 
position would increase the chance of a successful prosecution if an aggrieved patient were 
to challenge legally a refusal of therapy. Again, the existence of some harder evidence in 
the form of further RCTs clearly would assist in such a position. The dilemma is that these 
may never happen, for the ethical and possible legal consequences outlined above. 
 
  51 
6. FACTORS RELEVANT TO NHS POLICY 
 
There are no National Service Frameworks relating to the use of HBO and there is a lack of 
other national guidance. 
 
It is important that HBO is seen as part of a therapeutic continuum and not an isolated 
treatment modality. At present, whilst the Marx Protocols for the delivery of HBO are 
followed, there appears to be little in the way of a protocol identifying patients who would 
most benefit from therapy. Access to therapy, therefore, depends upon clinician familiarity 
with the existing facilities. The development of clear referral criteria is essential. 
 
Some patients access HBO at a facility where there is no physician present, e.g. in 
Sheffield. There may be issues of liability in terms of the adequacy of technical competence 
and personnel skills at the facility. In addition, there are issues relating to the 
appropriateness of patients receiving HBO where there is a lack of medical supervision. 
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7. OPTIONS FOR PURCHASERS/COMMISSIONERS  
  
There are four conditions in oral and maxillofacial surgery where HBO can be considered 
following treatment for oral cancer. They are: 
 
 the treatment of osteoradionecrosis;  
 prophylactically before and after radiotherapy which involves the mandible to prevent 
osteoradionecrosis; 
 the promotion of wound-healing; 
 before and after the placement of implants. 
 
A number of options are available to purchasers: 
 
1. Do not purchase HBO for any of the four conditions 
 
This option would, however, prevent further evidence being produced. Given that existing 
evidence supports the use of HBO in some situations, this does not appear to be an ethical 
way forward. 
 
2. Purchase HBO only within the context of clinical trials 
 
The number of patients is small and this would make the recruitment to clinical trials within 
the UK extremely difficult. 
  
3. Purchase HBO for selected conditions, on the basis of agreed criteria, as follows: 
 
 the treatment of established ORN which has failed to respond to conservative therapy 
within a defined time-period; 
 do not purchase for the prevention of ORN, but purchase for the treatment of 
established ORN; 
 purchase for complicated wound-healing.  
 
Further work is required to determine the appropriateness of purchasing for implants. 
Current evidence suggests than only patients receiving high doses of radiation (say >65Gy) 
will benefit. In many health authorities limited funding for implants is currently restricting the 
number of patients offered implants.  
The demand for HBO in association with the placement of implants is likely to increase, if 
further funding is made available. The use of implants offers the patient the best option for 
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quality reconstruction. The number of cases will increase with the improvement in surgical 
skills and reconstructive techniques. A possible way forward is to recruit patients to multi-
centre studies. 
 
In addition, there should be consideration at a regional and national level of the need to 
identify recognised centres for the delivery of HBO therapy. 
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8. DISCUSSION and CONCLUSIONS 
 
The evidence for the use of HBO in the treatment of oral cancer is limited. Whilst there is 
some research evidence available, much is still unknown and there is a need for further 
research into its use in the treatment of patients with oral cancer. In relation to the treatment 
of ORN, the weight of evidence supports the effectiveness of HBO; but suggests that it 
might not be necessary for all patients. For the prevention of ORN, the evidence is unclear. 
Management protocols based on careful wound care and good surgical technique should be 
used to minimise the risk of ORN. The use of HBO should not be used as a substitute for 
the high quality management of patients. There is limited evidence to support the use of 
HBO prior to the placement of endosseous implants, but further evidence is required.  
 
The number of patients who may benefit from therapy is small; however, the impact of oral 
cancer upon a person's physical and psychological well-being is great. There is potential to 
increase the number of potential patients by including people affected by head and neck 
cancer as well as those with oral cancer. In addition, there is a wider pool of patients who 
may benefit from the use of endosseous implants. Current funding of this reconstructive 
procedure is limited.  
 
There is a need for better information systems pertaining to the diagnosis and management 
of people with head and neck cancer. There appears to be a lack of criteria for the use of 
HBO and work at a local and national level is required in order to produce clinical consensus 
on treatment. As this procedure is not without risk, patients need to have access to 
comprehensive information and this is difficult in the absence of agreed clinical guidance. 
 
At present, the service provided does not allow equitable access across the Trent Region. In 
some units, a physician is not present when the treatment is given.  
 
In summary, it is recommended that HBO in the treatment of oral cancer is used in the 
context of a clear statement of clinical practice, fully informed consent, comprehensive 
information and the collection of clinical data which allows the analysis of benefits and risks. 
Patients should only receive HBO from a unit which has the necessary quality controls, both 
with respect to the pressure used and patient observation.  
  55 
REFERENCES  
 
 
1  Sheps SB. Hyperbaric Oxygen for Osteomyelitis and Osteoradionecrosis. 
1992; British Columbia Office of Health Technology Assessment discussion 
paper 92:3. 
 
2  MacFarlane GM, Boyle P, Scully C. Rising mortality from cancer of the tongue 
in young Scottish males. Lancet 1987; 912. 
 
3  Moller H. Changing incidence of cancer of the tongue, oral cavity and pharynx 
in Denmark. Journal of Oral Pathology and Medicine 1989; 18: 224-229. 
 
4  ONS Cancer Statistics Registrations. 1999; Series MB1. 
 
5  Cancer Research Campaign. Oral Cancer in the United Kingdom. 1993; CRC 
Factsheet No. 14. 
 
6  Binnie WH, Rankin KV, McKenzie IC. Aetiology of oral squamous cell 
carcinoma. Journal of Oral Pathology 1983; 12: 11-26. 
 
7 Lindquist C, Teppo L. Epidemiological evaluation of sunlight as a risk factor 
for oral cancer. British Journal of Cancer 1978; 37: 983-989. 
 
8  Scully C, Ward-Booth RP. Detection and Treatment of Early Cancers. Critical 
Reviews in Oncology/Hematology 1995; 21: 63-75. 
 
9  WHO Collaborating centre for oral precancerous lesions. Definition of 
leukoplakia and related lesions: an aid to studies in oral precancer. Oral 
Surgery 1978; 46: 518-539. 
 
10  Axell T, Pindborg JJ, Smith CJ, van der Waal I. Oral white lesions with special 
reference to precancerous and tobacco- related lesions: conclusions of an 
international symposium held in Uppsala, Sweden, May 18-21 1994. 
International Collaborative Group on Oral White Lesions. Journal of Oral 
Pathological Medecine. 1996 Feb; 25(2): 49-54. 
 
11  Cawson RA. Leukoplakia and oral cancer. Proceedings of the Royal Society 
of Medicine 1969; 62: 610-615. 
 
12  Elwood JM, Pearson JCG, Skipper I, et al. Alcohol, smoking, social and 
occupational factors in the aetiology of cancer of the oral cavity, larynx and 
pharynx. Intternational Journal of Cancer 2019; 34: 603-612. 
 
13  Rothman KJ. The effect of alcohol consumption on the risk of cancer of the 
head and neck. Laryngoscope 1978; 88: 51-55. 
 
  56 
14  Rich AM, Radden BG. Squamous cell carcinoma. A review of 24 cases in 
Australia. Journal of Oral Pathology 1984; 13: 459-471. 
 
15  Notani PN, Joyant K. Role of diet in upper aerodigestive tract cancers. 
Nutrition and Cancer 1987; 4: 59-70 ONS. 
 
16  Scully C. Sources and Patterns of Referrals of Oral Cancer : role of general 
practioners. British Medical Journal 1986; 293: 599-601. 
 
17  Costantino PD, Friedman CD, Steinberg MJ. Irradiated bone and its 
management. Otolaryngologic Clinics of North America 1995; 28: 1021-1038. 
 
18  Dempsey J, Haynes N, Smith T, et al. Cost effectiveness analysis of 
hyperbaric therapy in osteoradionecrosis. Canadian Journal of Plastic 
Surgery 1997; 5: 221. 
 
19  Clayman L. Clinical controversies in oral and maxillofacial surgery: Part two. 
Management of dental extractions in irradiated jaws: a protocol without 
hyperbaric oxygen therapy. Journal of Oral and Maxillofacial Surgery 1997; 
55: 275-281. 
 
20  Brown DH, Evans AW, Sandor GK. Hyperbaric oxygen therapy in the 
management of osteoradionecrosis of the mandible. Advances in Oto-Rhino-
Laryngology 1998; 54: 14-32. 
 
21  A code of good working practice for the operation and staffing of hyperbaric 
chambers for therapeutic purposes. 1994; ISSBN 1 873240 99 6. 
 
22  Bernstein EF, Sullivan FJ, Mitchell JB. Biology of chronic radiation effect on 
tissues and wound healing. Clinics in Plastic Surgery 1993; 20: 435-453. 
 
23  Moore MJ. The effect of radiation on connective tissue. Otolaryngol Clinics of 
North America 1984; 17: 389-399. 
 
24  Cohen L. Methods of investigating the vascular architecture of the mandible. 
Journal of Dental Research 1959; 38: 920-931. 
 
25  Bradley JC. Age changes in the vascular supply of the mandible. British 
Dental Journal 1972; 132: 142-144. 
 
26  ONS Report. Registrations of cancer diagnosed in 1993-1996, England and 
Wales Health Statistic Quarterly. 1999; 4: 59-70. 
 
27  Marx RE, Ames JR. The use of hyperbaric oxygen therapy in bony 
reconstruction of the irradiated and tissue-deficient patient. Journal of Oral 
and Maxillofacial Surgery 1982; 40: 412-420. 
 
  57 
28  Knighton DR, Silver IA, Hunt TK. Regulation of wound healing angiogenesis: 
Effect of oxygen gradients and inspired oxygen concentrations. Surgery 1981; 
90: 262-270. 
 
29  Kindwall EP. Hyperbaric oxygen's effect on radiation necrosis. Clinics in 
Plastic Surgery 1993; 20: 473-483. 
 
30  Marx RE, Johnson RP. Dental extractions and radiotherapy for head and 
neck cancers -reply. Oral Surgery, Oral Medicine, Oral Pathology, Oral 
Radiology and Endodontics 1988; 66: 177-178. 
 
31  Marx RE, Ehler WJ, Tayapongsak P, et al. Relationship of oxygen dose to 
angiogenesis induction in irradiated tissue. American Journal of Surgery 
1990; 160: 519-524. 
 
32  Giebfried JW, Lawson W, Biller HF. Complications of hyperbaric oxygen in 
the treatment of head and neck disease. Otolaryngology - Head and Neck 
Surgery 1986; 94: 508-512. 
 
33  Foster JH. Hyperbaric-oxygen therapy - contraindications and complications. 
Journal of Oral and Maxillofacial Surgery 1992; 50: 1081-1086. 
 
34  Headley DB, Gapany M, Dawson DE, et al. The effect of hyperbaric-oxygen 
on growth of human squamous-cell carcinoma xenografts. Archives of 
Otolaryngology-Head and Neck Surgery 1991; 117: 1269-1272. 
 
35  Blanshard J, Toma A, Bryson P, et al. Middle ear barotrauma in patients 
undergoing hyperbaric oxygen therapy download full text of article. Clinical 
Otolaryngology 1996; 21: 400-403. 
 
36  Ross ME, Yolton DP, Yolton RL, et al. Myopia associated with hyperbaric 
oxygen therapy. Optometry and Vision Science 1996; 73: 487-494. 
 
37  Beumer J, Harrison R, Sanders B, et al. Osteoradionecrosis: predisposing 
factors and outcomes of therapy. Head and Neck Surgery 1984; 6: 819-827. 
 
38  Epstein J, van der Meij E, McKenzie M, et al. Postradiation osteonecrosis of 
the mandible: a long-term follow-up study. Oral Surgery, Oral Medicine, Oral 
Pathology, Oral Radiology, and Endodontics 1997; 83: 657-662. 
 
39  Marx RE. A new concept in the treatment of osteoradionecrosis. Journal of 
Oral and Maxillofacial Surgery 1983; 41: 351-357. 
 
40  van Merkesteyn JP, Bakker DJ, Borgmeijer-Hoelen AM. Hyperbaric oxygen 
treatment of osteoradionecrosis of the mandible. Experience in 29 patients. 
Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and 
Endodontics 1995; 80: 12-16. 
 
41  Wood GA, Liggins SJ. Does hyperbaric oxygen have a role in the 
management of osteoradionecrosis? British Journal of Oral and Maxillofacial 
  58 
Surgery 1996; 34: 424-427. 
 
42  Mitton C. Hyperbaric Oxygen Treatment in Alberta. 1998. 
 
43  Myers RAM, Schnitzer BM. Hyperbaric Oxygen Use Update 1984. Hyperbaric 
Oxygen Use 1984; 76: 83-95. 
 
44  Greenwood TW, Gilchrist AG. The effect of hyperbaric oxygen on wound 
healing following ionizing radiation. In Proceedings of the Fifth International 
Congress on Hyperbaric Medicine, vol 1. 1973; 253-263. 
 
45  Balogh JM, Sutherland SE. Osteoradionecrosis of the mandible: a review. 
Journal of Otolaryngology 1989; 18: 245-250. 
 
46  Grim PS, Gottlieb LJ, Boddie A, et al. Hyperbaric-oxygen therapy. Journal of 
the American Medical Association 1990; 263: 2216-2220. 
 
47  Marx RE, Kline SN. Principles and methods of osseous reconstruction. 
International Advances in Surgical Oncology 1983; 6: 167-228. 
 
48  Farmer JC, Jr., Shelton DL, Angelillo JD, et al. Treatment of radiation-induced 
tissue injury by hyperbaric oxygen. Annals of Otology, Rhinology and 
Laryngology 1978; 87: 707-715. 
 
49  Davis JC, Dunn JM, Gates GA, et al. Hyperbaric oxygen. A new adjunct in the 
management of radiation necrosis. Archives of Otolaryngology 1979; 105: 58-
61. 
 
50  Myers RA, Marx RE. Use of hyperbaric oxygen in postradiation head and 
neck surgery. NCI Monographs 1990; 151-157. 
 
51  Marx RE, Johnson RP. Problem Wounds in Oral and Maxillofacial Surgery: 
The Role of Hyperbaric Oxygen. In: Davis JC, Hunt TK. (eds.): Problem 
Wounds - The Role of Oxygen. New York: Elsevier; 1988; 65 - 124. 
 
52  Tibbles PM, Edelsberg JS. Medical progress - hyperbaric-oxygen therapy. 
New England Journal of Medicine 1996; 334: 1642-1648. 
 
53  London SD, Park SS, Gampper TJ, et al. Hyperbaric oxygen for the 
management of radionecrosis of bone and cartilage. Laryngoscope 1998; 
108: 1291-1296. 
 
54  Wong JK, Wood RE, McLean M. Conservative management of 
osteoradionecrosis. Oral Surgery, Oral Medicine, Oral Pathology, Oral 
Radiology and Endodontics 1997; 84: 16-21. 
 
55  Aitasalo K, Niinikoski J, Grenman R, et al. A modified protocol for early 
treatment of osteomyelitis and osteoradionecrosis of the mandible. Head and 
Neck-Journal for the Sciences and Specialties of the Head and Neck. 1998; 
20: 411-417. 
  59 
 
56  Thorn JJ, Kallehave F, Westergaard P, et al. The effect of hyperbaric oxygen 
on irradiated oral tissues: transmucosal oxygen tension measurements. 
Journal of Oral and Maxillofacial Surgery 1997; 55: 1103-1107. 
 
57  van Merkesteyn JPR, Bakker DJ, Borgmeijerhoelen AMMJ. Hyperbaric-
oxygen treatment of osteoradionecrosis of the mandible - experience in 29 
patients. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and 
Endodontics 1995; 80: 12-16. 
 
58  Mounsey RA, Brown DH, Odwyer TP, et al. Role of hyperbaric-oxygen 
therapy in the management of mandibular osteoradionecrosis. Laryngoscope 
1993; 103: 605-608. 
 
59  McKenzie MR, Wong FL, Epstein JB, et al. Hyperbaric oxygen and 
postradiation osteonecrosis of the mandible. European Journal of Cancer 
1993; Part B, Oral Oncolog: 201-207. 
 
60  Hart GB, Mainous EG. The treatment of radiation necrosis with hyperbaric 
oxygen (OHP). Cancer 1976; 37: 2580-2585. 
 
61  Mainous EG, Hart GB. Osteoradionecrosis of the mandible. Treatment with 
hyperbaric oxygen. Archives of Otolaryngology 1975; 101: 173-177. 
 
62  Maxymiw WG, Wood RE, Liu FF. Postradiation dental extractions without 
hyperbaric-oxygen. Oral Surgery, Oral Medicine, Oral Pathology, Oral 
Radiology and Endodontics 1991; 72: 270-274. 
 
63  Stofka S, Liang TS. The use of hyperbaric oxygen therapy before dental 
treatment in postirradiated patients. Compendium 1994; 15: 200-207. 
 
64  Kraut RA. Prophylactic hyperbaric oxygen to avoid osteoradionecrosis when 
extractions follow radiation therapy. Clinical Preventive Dentistry 1985; 7: 17-
20. 
 
65  Marx RE, Johnson RP, Kline SN. Prevention of osteoradionecrosis - a 
randomized prospective clinical- trial of hyperbaric-oxygen versus penicillin. 
Journal of the American Dental Association 1985; 111: 49-54. 
 
66  Granstrom G, Tjellstrom A, Branemark PI. Osseointegrated implants in 
irradiated bone: a case-controlled study using adjunctive hyperbaric oxygen 
therapy. Journal of Oral and Maxillofacial Surgery 1999; 57: 493-499. 
 
  60 
67  Jisander S, Grenthe B, Alberius P. Dental implant survival in the irradiated 
jaw: a preliminary report. International Journal of Oral and Maxillofacial 
Implants 1997; 12: 643-648. 
 
68  Marker P, Siemssen SJ, Bastholt L. Osseointegrated implants for prosthetic 
rehabilitation after treatment of cancer of the oral cavity. Acta Oncologica 
1997; 36: 37-40. 
 
69  Arcuri MR, Fridrich KL, Funk GF, et al. Titanium osseointegrated implants 
combined with hyperbaric oxygen therapy in previously irradiated mandibles. 
Journal of Prosthetic Dentistry 1997; 77: 177-183. 
 
70  Esser E, Wagner W. Dental implants following radical oral cancer surgery and 
adjuvant radiotherapy. International Journal of Oral and Maxillofacial Implants 
1997; 12: 552-557. 
 
71  Taylor TD, Worthington P. Osseointegrated implant rehabilitation of the 
previously irradiated mandible: results of a limited trial at 3 to 7 years. Journal 
of Prosthetic Dentistry 1993; 69: 60-69. 
 
72  Neovius EB, Lind MG, Lind FG. Hyperbaric oxygen therapy for wound 
complications after surgery in the irradiated head and neck: a review of the 
literature and a report of 15 consecutive patients. Head and Neck 1997; 19: 
315-322. 
 
73  Marx RE. Clinical application of bone biology to mandibular and maxillary 
reconstruction. Clinics in Plastic Surgery 1994; 21: 377-392. 
 
74  Schwartz HC. Treatment of osteoradionecrosis with measures other than 
hyperbaric oxygen. Proceedings of First International Congress on 
Maxillofacial Prosthetics. 1995; 192-198. 
 
75  Clayman L. Management of dental extractions in irradiated jaws: a protocol 
without hyperbaric oxygen therapy. Journal of Oral and Maxillofacial Surgery 
1997; 55: 275-281. 
 
76  Lambert PM, Intriere N, Eichstaedt R. Clinical controversies in oral and 
maxillofacial surgery: Part one. Management of dental extractions in 
irradiated jaws: a protocol with hyperbaric oxygen therapy. Journal of Oral 
and Maxillofacial Surgery 1997; 55: 268-274. 
 
77  Hampson NB. Hyperbaric oxygen therapy: 1999 committee report. 
Kensington MD: Undersease and Hyperbaric Medical Society 1999. 
 
 
 
  61 
APPENDIX A RESULTS OF A SURVEY ON THE USE OF HYPERBARIC 
OXYGEN IN THE TREATMENT OF PATIENTS WITH ORAL 
CANCER IN THE TRENT REGION 
 
 
31 questionnaires were sent to ENT and Oral and Maxillofacial surgeons in the Trent 
Region and 18 were returned. The contents were as follows: 
 
1. Do you refer patients with oral cancer for hyperbaric oxygen therapy? 
 
14 respondents indicated they did refer patients (oral and maxillofacial 
surgeons); 4 respondents (ENT surgeons) did not. 
 
2. Do you refer patients for hyperbaric oxygen therapy: 
 
 a) in the treatment of osteoradionecrosis? 
 
13 respondents indicated that they did. 
 
 b) pre and post radiation therapy in order to prevent 
osteoradionecrosis? 
 
4 respondents indicated that they did. 
 
 c) pre and post surgery in order to promote wound healing? 
 
6 respondents utilised HBO therapy in this way. 
 
 d) Prior to the placement of endosseous implants in order to improve 
implant survival? 
 
9 respondents replied that they did. 
 
3. Are there agreed referral criteria for patients? 
 
7 respondents indicated that referral criteria were in place. 
 
4. Is there an agreed protocol for hyperbaric oxygen therapy, e.g. exposure 
time: number of exposures? 
 
10 respondents replied that protocols existed. 
 
5. How many patients have you referred for therapy in the last 12 months? 
 
 No. Patients Referred Consultants Referring 
 
 
 0 1  
 1 5  
 2 3  
 3 1  
 4 2  
 10 1  
 Unknown 1  
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6. Where do you refer patients for hyperbaric oxygen therapy? 
 
The centres identified were: 
 
   Plymouth 
 
   Peterborough 
 
   Hull Mobile Unit 
 
   Sheffield Multiple Sclerosis Unit 
 
   Ellesmere Port 
 
   Lincoln. 
 
7. Have you any comments to make in relation to this therapy? 
 
   Efficacy is proven in the literature. 
 
   I would be keen to learn of site, availability, costings and protocols. 
 
   Information regarding questions relating to the use for wound 
healing and prior to implant placement. 
 
   Our experience has been confined to very long-term complications 
of radiotherapy (the last case 15 years or so). Revascularisation 
with tissue transfer has been used instead on a few patients. 
 
   It has proven effective in certain patients, but its use is controversial 
in other areas within the oral cavity. I am sure more patients would 
be sent if facilities were better and the costs lower. 
 
   There is an increasing need. 
 
   Unless there are other uses for hyperbaric oxygen therapy – other 
then oral cancer, it would seem sensible to use local facilities in 
Peterborough. 
 
   I would like to see a physician staffed unit locally (we do not use it 
enough). There is some evidence that it may reduce recurrence in 
cancer patients used in combination with radiotherapy. 
 
   The hyperbaric 02 facilities at Lincoln are not appropriate, because 
the pressure cannot be raised to 2.2 – 2.4 atmospheres; we will 
have to refer elsewhere now. 
 
   Other metabolic bone disease, e.g. osteopetrosis with 
osteomyelitis. 
 
   A valuable addition to our armament arum that is clinically effective. 
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APPENDIX B MARX PROTOCOL FOR THE TREATMENT OF ESTABLISHED 
OSTEORADIONECROSIS
39,77
 
 
 
Marx introduced a staging system, relative to the severity of the mandibular necrosis, 
permitting a plan of therapeutic intervention which is a logical outgrowth of the stage of 
necrosis. Stage I mandibular necrosis includes those patients who have had exposed bone 
for six months or more. Stage II patients represent those who do not resolve when treated 
as Stage I, Stage III patients are those with poor prognostic factors, including pathologic 
fracture, orocutaneous fisulae or evidence of osteolytic involvement extending to the inferior 
mandibular border. 
 
Stage I 
When patients fit the appropriate selection criteria, they enter the HBO treatment protocol 
as Stage I patients. In Marx’s protocol, these patients begin with a course of 30 HBO 
treatments at 2.4 ata for 90 oxygen minutes. If progression is satisfactory, including 
coverage of exposed bone, another 10 treatments are administered. If the patient’s 
progress has not been satisfactory at 30 treatments, he or she is advanced to Stage II. 
 
Stage II 
In Stage II, a local surgical debridement (typically a transpolar alveolar sequestectomy) is 
performed after 30 treatments. If healing progresses satisfactorily, this group typically 
completes another 10 HBO2 treatments post-debridement. 
 
Stage III 
For patients who do not progress appropriately in Stage II or for patients who present with 
advanced disease initially, treatment is delivered according to stage III guidelines. Patients 
received 30 HBO treatments as in Stage II, then undergo a transoral partial 
mandibulectomy. Ten additional post-operative HBO sessions are delivered. These patients 
then enter into a mandibular reconstructive phase. About 10 weeks following completion of 
all 40 HBO treatments, the patient undergoes a reconstruction with a transcutaneous 
approach to avoid oral flora contamination. This surgery is done utilising freeze-dried 
cadaveric bone as the carrier tray, into which the patient’s own bone (harvested from the 
iliac crest with both cortical and cancellous components) is grafted. The patient then 
completes a course of 20 post-reconstruction HBO treatments. 
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Other papers published by the Trent Institute for Health Services Research are listed 
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Guidance Notes for Purchasers  
 
96/01 Working Group on Acute Purchasing: The Use of DNase in   
  
£6.00 
 Cystic Fibrosis (1996) by JN Payne, S Dixon, NJ Cooper and   
 CJ McCabe.  
       
96/02 Working Group on Acute Purchasing: Tertiary Cardiology (1996)    £6.00 
 by J Tomlinson, J Sutton and CJ McCabe.  
  
96/03 Working Group on Acute Purchasing: The Use of Cochlear     £6.00 
 Implantation (1996) by Q Summerfield and J Tomlinson.  
  
96/04 Working Group on Acute Purchasing: Statin Therapy / HMG Co-A   
  Reductase Inhibitor Treatment in the Prevention of Coronary Heart 
Disease 
£6.00 
 (1996) by MD Pickin, JN Payne, IU Haq, CJ McCabe, SE Ward, PR Jackson  
 and WW Yeo.  
  
97/01 Working Group on Acute Purchasing: The Clinical and Cost-effectiveness   £10.00 
 of Computed Tomography in the Management of Transient Ischaemic   
 Attack and Stroke (1997) by A Ferguson and CJ McCabe. Series Editor: Nick 
Payne. 
 
  
97/02 Working Group on Acute Purchasing: Prostacyclin in the Treatment of    £10.00 
 Primary Pulmonary Hypertension (1997) by TW Higenbottam, SE Ward,   
 A Brennan, CJ McCabe, RG Richards and MD Stevenson. Series Editor: Nick 
Payne. 
 
  
97/03 Working Group on Acute Purchasing: The Use of Riluzole in the Treatment £10.00 
 of Amyotrophic Lateral Sclerosis (Motor Neurone Disease) (1997) by J Chilcott,  
 P Golightly, D Jefferson, CJ McCabe and S Walters. Series Editor: Nick Payne. 
 
  
97/04 Working Group on Acute Purchasing: Recombinant Factor VIII Versus    £10.00 
 Plasma Derived Factor VIII in the Management of Haemophilia A: An   
 Examination of the Costs and Consequences (1997) by C Green and   
 RL Akehurst. Series Editor: Nick Payne.  
  
97/05 Working Group on Acute Purchasing: The Use of Cisplatin and Paclitaxel £10.00 
 as a First Line Treatment in Ovarian Cancer (1997) by SM Beard, R Coleman,   
 J Radford and J Tidy. Series Editor: Nick Payne.  
  
97/06 Working Group on Acute Purchasing: The Use of Alpha Interferon in the   
 Management of Chronic Myeloid Leukaemia (1997) by RG Richards and  
£10.00 
 CJ McCabe. Series Editor: Nick Payne.  
  
97/07 Working Group on Acute Purchasing: Spinal Cord Stimulation in the    £10.00 
 Management of Chronic Pain (1997) by J Tomlinson, CJ McCabe and B Collett. 
Series Editor: Nick Payne. 
 
  
97/08 Working Group on Acute Purchasing: The Use of Growth Hormone in Adults   £5.00 
 (1997) by JN Payne and RG Richards. Series Editor: Nick Payne.  
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97/09 Working Group on Acute Purchasing: A Review of the Use of Donepezil in the   £10.00 
 Treatment of Alzheimer’s Disease (1997) by FA Pitt, J Chilcott, P Golightly,   
 J Sykes, M Whittingham. Series Editor: Nick Payne.  
  
97/10 Working Group on Acute Purchasing: The Use of Bone Anchored Hearing Aids   £10.00 
 (1997) by NJ Cooper, J Tomlinson and J Sutton. Series Editor: Nick Payne.  
  
98/01 Working Group on Acute Purchasing: A Review of the Use of Current Atypical  
 Antipsychotics in the Treatment of Schizophrenia (1998) by S Beard, J Brewin,  
 C Packham, P Rowlands, P Golightly. Series Editor: Nick Payne. 
£10.00 
  
98/02 Working Group on Acute Purchasing: Internal Fixation of Tibial Shaft and   
 Distal Radius Fractures in Adults (1998) by N Calvert, P Triffit, S Johnstone,  
 RG Richards. Series Editor: Nick Payne. 
£10.00 
  
 
98/04 Working Group on Acute Purchasing: The Effectiveness of High Dose 
Chemotherapy and Autologous Stem Cell Transplantation in the Treatment of 
Hodgkin’s Disease and Non-Hodgkin’s Lymphoma (1998) by S Beard, P Lorigan, 
A Simms, F Sampson. Series Editor: Nick Payne. 
 
£10.00 
 
98/05 Working Group on Acute Purchasing: Angiotensin-Converting Enzyme (ACE) 
Inhibitors in Heart Failure: Reducing Mortality and Costs to the NHS (1998) by N 
Calvert, J Cornell, C Singleton. Series Editor: Nick Payne. 
 
 
£10.00 
98/06 Working Group on Acute Purchasing The Use of Ultrasound (Viability) Scans In 
Early Pregnancy Bleeding (1998) by N Calvert, C Singleton, P Tromans. Series 
Editor: Nick Payne. 
 
£10.00 
98/08 Working Group on Acute Purchasing: The Effectiveness of High Dose 
Chemotherapy with Autologous Stem Cell / Bone Marrow Transplantation in the 
Treatment of Multiple Myeloma (1998) by S Beard, F Sampson, E Vandenberghe 
and F Scott. Series Editor: Nick Payne. 
 
£10.00 
98/10 Working Group on Acute Purchasing: Supplementary Document: The Use of 
Paclitaxel in the First Line Treatment of Ovarian Cancer (1998) by S Beard, 
 R Coleman, J Radford and J Tidy. Series Editor: Nick Payne. 
 
£10.00 
98/11 Working Group on Acute Purchasing: The Use of Fluoridated School Milk in the 
Prevention of Dental Caries (1998) by N Calvert and N Thomas. Series Editor: 
Nick Payne. 
 
£10.00 
99/01 Working Group on Acute Purchasing: The Role of Antileukotrienes in the 
Treatment of Chronic Asthma (1999) by M Stevenson, R Richards, S Beard. 
Series Editor: Nick Payne. 
 
£15.00 
99/02 Working Group on Acute Purchasing: Partial Hepatectomy for Liver Metastases 
(1999) by S Beard, M Holmes, A Majeed, C Price. Series Editor: Nick Payne. 
 
£15.00 
99/03 Working Group on Acute Purchasing: A Review of the Use of Propentofylline in 
the Treatment of Dementia (1999) by J Chilcott, K Perrett, P Golightly, J Sykes 
and  
M Whittingham. Series Editor: Nick Payne. 
 
£15.00 
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99/04 Working Group on Acute Purchasing: The Use of Routine Anti-D prophylaxis 
Antenatally to Rhesus Negative Women (1999) by M Allaby, K Forman, S Touch 
and J Chilcott. Series Editor: Nick Payne. 
 
£15.00 
99/05 Working Group on Acute Purchasing: Magnetic Resonance Imaging (MRI) in the 
Management of Knee Disorders (1999) by SM Beard, I Perez , S Touch and  
D Bickerstaff. Series Editor: Nick Payne. 
 
£15.00 
99/06 Working Group on Acute Purchasing: The Effectiveness of Surgery in the 
Management of Epilepsy (1999) by J Chilcott, S Howell, A Kemeny, C Rittey and 
Richards C. Series Editor: Nick Payne. 
 
£15.00 
99/07 Working Group on Acute Purchasing: Tacrolimus and Mycophenolate Mofetil as 
Maintenance Immunosuppressants Following Renal Transplantation (1999) by  
J Chilcott, M Corcoran, KM Rigg, RP Burden. Series Editor: Nick Payne. 
 
£15.00 
99/08 Working Group on Acute Purchasing: The Use of Endovascular Stents for 
Abdominal Aortic Aneurysm (1999) by NW Calvert, M Lloyd Jones, S Thomas,  
RG Richards, JN Payne. Series Editor: Nick Payne. 
 
£15.00 
00/01 Working Group on Acute Purchasing: The Effectiveness of Intrathecal Baclofen in 
the Management of Patients with Severe Spasticity (2000) by FC Sampson,  
SH Touch, A Hayward, G Evans, R Morton, D Playford, M Vloeburghs, A Collett,  
P Critchley. Series Editor: Nick Payne. 
 
£15.00 
00/02 Working Group on Acute Purchasing: Summary of the Current Evidence of 
Comparative Effectiveness for SSRIs and TCAs in the First Line Treatment of 
Depression in Primary Care (2000) by S Beard, C McGarrity, S Touch. Series 
Editor: Nick Payne. 
 
£15.00 
  
 
Discussion Papers 
 
 
  
No. 1. Patients with Minor Injuries: A Literature Review of Options for their    £7.00 
 Treatment Outside Major Accident and Emergency Departments   
 or Occupational Health Settings (1994) by S Read.       
  
96/01  Working Group on Acute Purchasing: The Role of Beta Interferon    £7.50 
 in the Treatment of Multiple Sclerosis (1996) by RG Richards,   
 CJ McCabe, NJ Cooper, SF Paisley, A Brennan and RL Akehurst.   
  
96/02 The Mid-level Practitioner: A Review of the Literature on Nurse Practitioner   £10.00 
 and Physician Assistant Programmes (1996) by P Watson, N Hendey,   
 R Dingwall, E Spencer and P Wilson.    
  
96/03 Evaluation of two Pharmaceutical Care Programmes for People with   £10.00 
 Mental Health Problems Living in the Community (1996) by A Aldridge,     
 R Dingwall and P Watson.          
  
97/01 Working Group on Primary and Community Care Purchasing : Report of   £10.00 
  the Sub-Group on the promotion of Quality in Primary Care - Effective  
 Purchasing of Primary and Community Health Care: Promotion of Quality in   
 the Provision of Primary Care (1997) by S Jennings and M Pringle.  
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97/02 Working Group on Primary and Community Care Purchasing : Report of   £10.00 
  the Sub-Group on Information Needs for Health Needs Assessment and   
 Resource Allocation (1997) by T Baxter, A Howe, C Kenny, D Meechan,   
 M Pringle, P Redgrave, J Robinson and A Sims.  
  
98/01 Working Group on Primary and Community Care Purchasing : Hospital at Home - 
Lessons from Trent (1998) by I Perez, A Wilson, A Sims and R Harper. 
£10.00 
 
00/01 Genetic Counselling: A Review of the Literature (2000) by A Pilnick, R Dingwall, E 
Spencer and R Finn. 
 
£15.00 
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